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SUMMARY 
Background: Polycystic ovary syndrome (PCOS) is a disorder characterized by insulin 
resistance and hyperandrogenism, which leads to an increased risk of type 2 diabetes in 
later life. Androgens and insulin signalling affect brain function but little is known 
about brain structure and function in younger adults with PCOS. 
Aims and Methods: To establish whether young women with PCOS display altered 
white matter microstructure and cognitive function. Eighteen individuals with PCOS 
(age, 31 ± 6 y; body mass index [BMI] 30 ± 6 kg/m2) and 18 control subjects (age, 31 ± 
7 y; BMI, 29 ± 6 kg/m2), matched for age, IQ, and BMI, underwent anthropometric and 
metabolic evaluation, diffusion tensor MRI, a technique especially sensitive to brain 
white matter structure, and cognitive assessment. Cognitive scores and white matter 
diffusion metrics were compared between groups. White matter microstructure was 
evaluated across the whole white matter skeleton using tract-based spatial statistics. 
Associations with metabolic indices were also evaluated. 
 
Results: PCOS was associated with a widespread reduction in axial diffusivity 
(diffusion along the main axis of white matter fibres) and increased tissue volume 
fraction (the proportion of volume filled by white or grey matter rather than 
cerebrospinal fluid) in the corpus callosum. Cognitive performance was reduced 
compared with controls (first principal component, t = 2.9, P = .007), reflecting subtle 
decrements across a broad range of cognitive tests, despite similar education and 
premorbid intelligence. In PCOS, there was a reversal of the relationship seen in 
controls between brain microstructure and both androgens and insulin resistance. 
vii 
 
Conclusion: White matter microstructure is altered, and cognitive performance is 
compromised, in young adults with PCOS. These alterations in brain structure and 
function are independent of age, education and BMI. If reversible, these changes 
represent a potential target for treatment. 
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CHAPTER 1 COGNITIVE IMPAIRMENT 
1.1 Introduction 
Dementia affects around 7% of the general population over 65 years, and 30% of  
people over 80 years. The prevalence of dementia is expected to double over the next 
30 years, making disorders of cognition a priority for healthcare and social-care 
services. The two most common forms of dementia are Alzheimer’s disease (AD) and 
vascular dementia, accounting for over 75% of all dementia cases. Although they have 
been regarded as two separate entities for decades, it is now well known that both these 
conditions show mixed pathology suggesting a continuum in underlying pathologies 
ranging from pure vascular dementia to pure Alzheimer’s disease.  
There is growing interest in strategies to modify the environment in midlife to increase 
the probability of maintaining cognitive health in late life. Several potentially 
modifiable risk factors have been studied in relation to cognitive impairment and 
dementia in late life.  
1.2 Cardiometabolic Risk Factors 
1.2.1 Hypercholesterolaemia 
Several studies have showed an association between raised cholesterol levels and 
dementia [1, 2], AD [3] and vascular dementia [4, 5]. Whitmer et al. conducted a 
retrospective cohort study of 9000 participants who underwent health evaluations over 
a period of 9 years with ages between 40 to 44. Approximately 700 participants had 
dementia (8%) with high cholesterol being associated with a 20% to 40% increase in 
risk of dementia (HR 1.42 95% CI 1.22 to 1.66 for high cholesterol) [6].  
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   Fig 1.1 Causative risk factors linked to the development of cognitive impairment.  
   Modifiable risk factors can be addressed from as early as in utero to early middle  
   age to prevent the onset of cognitive decline. 
 
The Atherosclerosis Risk in Communities (ARIC) study was a prospective study 
looking at 11,000 participants aged between 46 to 70 [1]. The risk of dementia with 
hypercholesterolaemia  was modest (HR 1.7 in age < 55, 0.9 > 70) compared to other 
traditional risk factors such as diabetes (HR 3.4 in < 55, 2.0 in >or=70) and smoking 
(4.8 in < 55, 0.5 in >or=70). Some studies such as the Framingham study have failed to 
show a similar association [7]. Some have even shown a lower risk of dementia with 
high cholesterol levels [8]. These discrepancies may be related to study methodology, 
the definition of dementia used and the groups of subjects studied including the timing 
of the diagnosis of hypercholesterolaemia (midlife versus late life). Some longitudinal 
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studies have shown that the relationship may be bidirectional with high midlife serum 
total cholesterol (TC) associated with a high risk for subsequent dementia, and 
decreasing serum TC after mid life representing a risk marker for late-life cognitive 
impairment [2]. 
1.2.2 Diabetes Mellitus 
Diabetes is associated with an increased risk of cognitive decline and dementia [9-11]. 
The presence of diabetes confers a 20% to 40% increase in risk of dementia (HR 1.46, 
95% CI 1.19 to 1.79)[6]. A systematic review of 14 studies found that diabetes is 
associated with a 50 to 100 percent increase in risk of AD and of dementia overall, and 
a 100 to 150 percent increased risk of vascular dementia [12]. Diabetes is more 
commonly associated with cerebrovascular disease [13, 14] but one study has shown an 
association with hippocampal atrophy which is more commonly associated with 
Alzheimer’s disease [15]. Higher glucose levels have also been associated with risk of 
cognitive impairment and dementia in nondiabetic individuals, implicating a possible 
role of insulin resistance as the causative aetiology [16, 17]. A cross sectional study 
showed that chronically higher blood glucose levels were associated with worsening 
scores in delayed recall, learning ability and memory consolidation [17]. The Targeting 
INflammation Using SALsalate in CardioVascular Disease (TINSAL-CVD) trial 
showed significant decrements in cognitive function test scores for every 1% increase 
in Hba1C in a mixed cohort of male individuals on a background of metabolic 
syndrome and coronary artery disease with normoglycaemia, impaired fasting glucose 
and type 2 diabetes [18]. 
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1.2.3 Obesity and Body Mass Index (BMI) 
Over the past decade, obesity has been increasingly recognised as a potential risk factor 
for cognitive decline particularly in older individuals. In cross-sectional studies, 
elevated body mass index as well as the metabolic syndrome, have been associated with 
deficits in memory, executive function, processing speed, semantic fluency, and overall 
cognitive function [19, 20]. Most of these studies found that mid-life obesity increases 
the risk of dementia later in life.  In a 27-year follow up study of 10,276 participants , 
obesity was associated with an increased risk of dementia , HR=1.74 (95% CI 1.34-
2.26), as was being overweight , HR=1.35 (95% CI 1.14-1.60) [21]. This relationship 
was maintained even after controlling for hyperlipidaemia and diabetes. Increased BMI 
has also been linked to lower baseline cognitive function and increased five year 
cognitive decline in a population based study of 2223 healthy non-demented individuals 
aged 32 to 62 years after adjustment for age , sex, educational level blood pressure , 
diabetes and other psychosocial covariables [22].  Data from longitudinal studies have 
shown that an elevated BMI is an independent risk factor for accelerated brain atrophy 
and increased risk of cognitive decline [23, 24]. More recent studies suggest that the 
hormonal changes associated with obesity may mediate changes in cognitive function, 
of which insulin resistance is considered particularly relevant because of the link 
between metabolic syndrome and cognitive dysfunction [25, 26]. Cognitive domains 
affected include executive function [19], verbal fluency [27] and working memory [28]. 
Bove et al.[29] studied the effects of obesity on cognitive function in 49 young healthy 
lean and overweight women aged 20 – 45 years and found a significant negative 
association between visceral adiposity and performance in the domain of verbal 
learning and memory, after controlling for age and education. Additionally the degree 
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of insulin resistance was negatively associated with executive function domain. No 
association was noted between hormonal factors and cognitive function. These findings 
suggest a possible association between obesity and cognitive function in healthy young 
women of reproductive age group. The mechanism of cognitive dysfunction in young 
adults is not clear but important mediators such as insulin resistance may play a role 
through modulation of hippocampal synaptic plasticity [30], neuroinflammation and 
subsequent protein deposition [31] and may have gender specific effects due to 
interactions with gonadal steroids [32]. 
1.2.4 Hypertension 
High blood pressure raises the risks of vascular dementia and cognitive dysfunction in 
older adults, by acting on the cerebral vasculature and directly on the brain itself. The 
relationship between hypertension and dementia risk is not entirely clear but  
epidemiologic and treatment studies support this hypothesis [1, 6]. Data from the 
Framingham Heart Study indicates that attention and memory measures are inversely 
related to blood pressure levels and duration of hypertension[33]. The Honolulu Asia 
Aging Study found that every 10 mm Hg increase in systolic blood pressure was 
associated with a 9% increased risk for poor cognitive function [34].  Although most 
studies have studied middle aged or elderly subjects there is evidence to suggest that 
young adults may also be susceptible to the deleterious effects of hypertension on 
cognition. In a 20-year longitudinal study of 529 adults comprising two age groups (18 
to 46 and 47 to 83 years), higher levels of baseline systolic, diastolic, and mean blood 
pressure in both younger and older age groups were significantly associated with 
decline in one neuropsychological measure of cognitive ability, the visualisation/fluid 
abilities composite score [35]. 
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The pathophysiologic mechanisms linking hypertension and cognitive dysfunction may 
be direct or indirect. Long standing hypertension may indirectly increase the risk of 
atherosclerosis, stroke, or cerebral infarction, which in turn may cause cognitive decline 
[36]. Hypertension may have a direct effect on brain volume: a small study by 
Strassburger et al. reported that patients with hypertension (age 56 to 84) had smaller 
volumes of thalamic nuclei, larger volumes of cerebrospinal fluid in the cerebellum and 
temporal lobes and performed worse on language and memory tests. This suggests that 
the occipital and temporal regions  appear more vulnerable to brain atrophy due to the 
interactive effects of age and hypertension [37]. Progressive changes in cerebral blood 
flow in hypertensive individuals were observed compared to controls by Positron 
emission tomography (PET) scans and this correlated with the duration of hypertension 
[38]. Blood pressure lowering treatments have been associated with improved cognitive 
outcomes measured by MMSE [39-41] . 
1.2.5 Smoking 
Data regarding the impact of smoking on the risk of dementia are conflicting. 
Population-based evidence of an effect of smoking on cognitive function has been 
inconclusive, with most longitudinal studies reporting weak or no associations [42]. 
Several prospective studies have suggested that smoking in middle aged and elderly 
people is associated with an increased risk of dementia [1, 6, 43]. A meta-analysis of 19 
studies with at least 12 months of follow-up concluded that elderly smokers have 
increased risk of AD, vascular dementia and any dementia, with relative risks of 1.27 
(95% CI 1.02-1.60) to 1.79 (95% CI 1.43-2.23) [44]. Current smoking was also 
associated with greater yearly declines in Mini-Mental State examination scores. 
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Possible mechanisms include cerebral hypoxia resulting in free radical injury and 
microvascular disease [45]. 
 
1.3 Polycystic Ovary Syndrome 
1.3.1 Introduction  
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders 
seen in premenopausal women, and is  characterised by hyperandrogenism and chronic 
anovulation. The high prevalence of obesity and insulin resistance in these patients 
predisposes them to an increased risk of type 2 diabetes mellitus. An unfavourable  
metabolic profile persists after menopausal transition as a result of increased androgen 
levels and decreased oestrogen levels with further exacerbation of insulin resistance, 
chronic inflammation and adiposity. The estimated prevalence is between 5-10% in 
women of reproductive age although it may be as high as 15-20% depending on the 
diagnostic criteria used.  
1.3.2 Historical Overview and Diagnosis  
The first documented account of PCOS dates back to the period of Hippocrates (460-
377 BC) who noted “But those women whose menstruation is less than three days or is 
meagre, are robust, with a healthy complexion and a masculine appearance; yet they are 
not concerned about bearing children nor do they become pregnant ”[46]. However  
applying a diagnosis retrospectively must be undertaken with caution.  
The modern description of PCOS can be traced back to 1935 when Stein and Leventhal 
reported a case series of seven women aged between 20 and 33 years with infertility, 
amenorrhoea and bilateral polycystic ovaries at laporotomy. Four of the women were 
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noted to have hirsutism, one woman had acne and three were obese. This is thought to 
be the first definitive description of the syndrome, which thus bore the name ‘Stein-
Leventhal syndrome’ until the middle of the twentieth century when it became known 
as PCOS. Since it’s original definition in 1935, the definition of PCOS has undergone 
several revisions. At the National Institutes of Health (NIH) consensus conference held 
in 1990, PCOS was defined as chronic anovulation with clinical and/or biochemical 
hyperandrogenism, with exclusion of other mimicking aetiologies, such as thyroid or 
adrenal dysfunction [47]. In 2003, the Rotterdam European Society for Human 
Reproduction/American Society of Reproductive Medicine (ESHRE/ASRM)-sponsored 
PCOS consensus workshop group proposed that the diagnosis include two of the 
following three criteria: oligo- and/or anovulation, clinical and/or biochemical 
hyperandrogenism, and polycystic ovaries on ultrasound; other aetiologies must be 
excluded.(Please see Table 2.1) The Rotterdam criteria extended the diagnosis of PCOS 
to women with oligo-ovulation and polycystic ovaries (non hyperandrogenic) as well as 
to women with hyperandrogenism and polycystic ovaries (ovulatory) neither of which 
would have met the narrower NIH criteria for PCOS. These broader criterion have also 
led to the argument that the expanded Rotterdam definition can result in an 
overdiagnosis or misdiagnosis of PCOS, and the different phenotypes may not have 
similar risks of long term metabolic complications. The diagnostic criteria were 
updated in 2006 by the Androgen Excess and PCOS society (AE-PCOS). Outlined in 
Table 1.1 are the main consensus groups and the definitions of PCOS that were agreed 
upon. The Rotterdam criteria include a broader spectrum of PCOS than the NIH and 
AE-PCOS society criteria, as hyperandrogenism does not need to be present for the 
diagnosis. In December 2013, the Endocrine Society endorsed the Rotterdam criteria 
for the diagnosis of PCOS in pre-menopausal women [48].  
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Table 1.1 Diagnosis of Polycystic Ovary Syndrome 
 
Consensus Group   Year   Criteria 
 
 
National Institute of Health (NIH) 1990   Chronic anovulation and 
  
Bethesda, USA [47]      Clinical and/or biochemical signs of 
 hyperandrogenism and 
 
 Exclusion of other aetiologies* 
 
 
 
European Society for Human  2003   Oligo- and/or anovulation and/or    
Reproduction and Embryology and 
the American Society for     Clinical and/or biochemical signs of  
Reproductive Medicine      hyperandrogenism and/or 
 
Rotterdam [49]       Polycystic Ovaries and 
  
 Exclusion of other aetiologies* 
 
        (2 or more of the first three criteria  
 must be present and  the exclusion 
 of other  aetiologies) 
 
 
 
The Androgen Excess and PCOS 2006  Hyperandrogenism (clinical and /or 
Society (AE-PCOS)[50]    biochemical) and 
     
Ovarian dysfunction (oligo-anovulation 
       and/or polycystic ovaries) and  
 
Exclusion of other aetiologies* and ** 
 
 
 
*Congenital Adrenal Hyperplasia, Androgen secreting neoplasms, Cushing’s syndrome, 
Thyroid dysfunction, Hyperprolactinaemia, Idiopathic Hirsutism and **Syndromes of severe 
insulin resistance 
 
 
1.3.3  Limitations of Research 
 
PCOS is a syndrome and not a disease entity. Its aetiology is complex, heterogeneous, 
and poorly understood. There are three definitions for PCOS currently in use that 
variably rely on androgen excess, chronic anovulation, and PCO to make the diagnosis. 
10 
 
Different phenotypes exist depending on the diagnostic criteria used and this may result 
in different risk and comorbidity profiles. The Endocrine Society guidelines state that 
biochemical hyperandrogenism refers to an elevated serum androgen level and includes 
an elevated total, bioavailable or free serum testosterone level [48]. The guideline 
acknowledges that there is no absolute level which is diagnostic of PCOS due to 
variability in testosterone levels and the poor standardisation of assays [51].The 
ultrasound criteria is also a subject of debate with differences across study groups as to 
the number of follicles (presence of 12 or more follicles 2-9mm in diameter and /or an 
increased ovarian volume >10ml, without a cyst or dominant follicle) in either 
ovary)[52]. This has implications in interpreting published research as the diagnostic 
criteria used may vary from one study to another. 
 
1.3.4 Pathogenesis 
Despite the high prevalence and significant morbidity resulting from both reproductive 
and hyperandrogenic features and the associated cardiovascular risk, the aetiology of 
PCOS remains incompletely understood. As PCOS is a heterogeneous disorder, the 
underlying pathophysiology of this condition is yet to be determined with the aetiology 
likely to be multifactorial. Several theories have been explained to determine the 
pathogenesis of PCOS focussing on the following observed physiological 
abnormalities: hypersecretion of Luteinising hormone (LH), increasing ovarian 
androgen production and insulin resistance. Other hypotheses include prenatal 
androgen exposure, low birth weight and premature pubarche. 
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Fig 1.2 Pathophysiology of Polycystic Ovary Syndrome 
1.3.4.1 Abnormalities in hypothalamic pituitary function 
Increasing LH relative to follicle-stimulating hormone (FSH) was the first laboratory 
abnormality identified in classic PCOS. This has been attributed to an increased 
gonadotrophin-releasing hormone (GnRH) pulse frequency from the hypothalamus 
which increases production of LH relative to FSH [53, 54]. Elevated LH is thought to 
play a role in the pathogenesis of PCOS by increasing androgen production and 
secretion by ovarian theca cells [55, 56]. Patients with PCOS have an increased LH 
pulse frequency and amplitude [57]. Some lines of evidence argue against this 
hypothesis. About half of patients with PCOS, principally obese patients, do not have 
elevated LH levels or abnormal gonadotrophin responses to GnRH agonist testing [55, 
57]. Furthermore, about half of PCOS subjects with a documented ovarian source of 
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hyperandrogenism were demonstrated to have normal LH levels and LH responses to a 
GnRH agonist test, suggesting that the ovarian dysfunction is independent of LH 
excess. 
 
1.3.4.2 Androgen production by the ovaries 
Hyperandrogenism is a central feature of most phenotypes of PCOS. In PCOS 
androgens (androstenedione and testosterone) are predominantly secreted by the ovaries 
and to a lesser degree the adrenals [58]. This pattern differs from that in pre-
menopausal women where the androgen secretion are equally contributed to by the 
ovaries and the adrenals. Insulin resistance does not exclusively contribute to the 
development of PCOS [59]. In the ovary, theca cells synthesise androgens and the 
granulosa cells synthesise oestrogens. The theca cells are stimulated by LH to produce 
androstenedione mediated by cytochrome P-450c17. Androstenedione is then converted 
to testosterone by 17 β-hydroxysteroid dehydrogenase (17β) or aromatised by 
cytochrome P-450arom to form oestrone. Oestrone is then converted to oestradiol also 
within the granulosa cell. FSH regulates the aromatase activity of the granulosa cells. In 
normal women androstenedione is preferentially converted to oestradiol. 
In PCOS, LH levels are elevated so the theca cells secrete increased quantities of 
androstenedione. In addition, thecal cells from women with PCOS are more sensitive to 
LH stimulation of androgen production [60]. Androstenedione secreted into the 
circulation by the ovary and adrenal can be converted to the potent androgen, 
testosterone, by most peripheral tissues. 
 
1.3.4.3 Insulin secretion and action 
 
PCOS  is  a  condition  in  which  tissue-selective  resistance  to  the  glucose-metabolic 
13 
 
 effects of insulin seems to be paradoxically associated with preserved ovarian 
sensitivity to insulin, suggesting a role for hyperinsulinemia in ovarian dysfunction [61-
64]. It is well known that hyperandrogenism correlates with hyperinsulinism in PCOS. 
This was first described by Burghen et al. who observed that patients with PCOS 
showed an exaggerated insulin response to an oral glucose tolerance test [65]. Several 
studies support this theory of compensatory hyperinsulinaemia, 50 to 70% of women 
with PCOS demonstrate clinically measurable insulin resistance in vivo independent of 
the degree of obesity. Theca cell secretion of androgens is stimulated by insulin and 
inhibits hepatic sex hormone binding globulin which results in an increase in free 
androgens [66-68]. Insulin may act as a cogonadotrophin to modulate ovarian 
steroidogenesis and the theca cells show hyper-responsiveness to the stimulatory effects 
of insulin on androgen secretion [69]. 
Although the aetiology of increased insulin resistance remains unclear, a post-binding 
defect in receptor signalling likely due to increased receptor and insulin receptor 
substrate-1 serine phosphorylation selectively affects metabolic but not mitogenic 
pathways in classic insulin target tissues and in the ovary [63]. Constitutive activation 
of serine kinases in the MAPK-ERK pathway may contribute to resistance to insulin's 
metabolic actions in skeletal muscle. Studies in adipose tissue have noted that, while 
insulin binding and the IRS/PI3-K/AKT insulin signalling pathway overall appears to 
be normal in PCOS, GLUT4 expression is significantly lower in PCOS patients and in 
control women with insulin resistance, although no defect in insulin receptor serine 
phosphorylation was observed [70]. Furthermore adipose tissue in  PCOS appears to 
have a differentially expressed miRNA profile with upregulation of miR-93 expression 
: the resultant dysregulation may play a role in the insulin resistance in PCOS [70]. 
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1.3.4.4 Prenatal Androgen Exposure 
Experimental evidence supports the hypothesis that the phenotypic expression of PCOS 
is strongly influenced by the intrauterine environment. This is based on animal models 
in which prenatal exposure to androgen excess leads to biochemical and clinical 
features of PCOS after birth [71]. Abbott and colleagues conducted experiments on 
rhesus monkeys demonstrating how prenatal administration of testosterone propionate 
recreated the PCOS phenotype in adulthood including hyperandrogenaemia, increased 
secretion of androgens in response to recombinant human chorionic gonadotrophin, 
oligo-ovulation and polyfollicular ovaries. These abnormalities were accompanied by 
accumulation of visceral fat, insulin resistance and impaired insulin secretion, 
especially in animals exposed to androgens early during gestation [72]. However these 
findings are yet to be confirmed in humans. A longitudinal study of 244 unselected girls 
recruited prenatally, failed to demonstrate an association between diagnosis of PCOS at 
age 15 and maternal hyperandrogenism throughout pregnancy or foetal 
hyperandrogenism at birth [73]. The diagnosis of PCOS in adolescents is challenging 
and a longer follow up and larger study group may have yielded different results. It is 
also possible that sampling of androgens during pregnancy missed a window of foetal 
or maternal androgen excess [74]. 
 
1.3.4.5 Low birth weight and premature pubarche 
It is hypothesised that foetal undernutrition selects for the thrifty genotype (genes 
important in energy conservation)[75]. It might appear that the activation of such genes 
would be beneficial at times of famine but can lead to obesity and diabetes in times of 
plenty. Girls with low birth weight and premature pubarche, experience menarche 
before 12years of age and develop hyperinsulinaemic androgen excess [76]. The 
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treatment of these group of individuals with metformin pre and during puberty has been  
shown to prevent the development of features of PCOS [77]. 
 
1.3.4.6 Genetic Factors 
PCOS is a genetically heterogeneous syndrome in which the genetic contributions 
remain incompletely described. The problems associated with genetic studies in PCOS 
relate to it’s heterogeneity, difficulty with retrospective diagnosis in post-menopausal 
women, associated subfertility, an incompletely understood aetiology and gene effect 
size. 
There is often a clustering of PCOS within families [78, 79] and studies indicate that an 
autosomal dominant mode of inheritance occurs for some families with this disease. 
Twin studies have shown a heritability of 75% for PCOS with a correlation of 0.71 
between monozygotic twins and 0.38 between dizygotic twins [80]. Many published 
genetics studies in PCOS have been underpowered, and the results of published 
candidate gene studies have been disappointing. 
An initial GWAS in China found association of PCOS (Rotterdam criteria) with the 
following three loci: 2p16.3 (luteinising hormone/choroidogonadotrophin receptor; 
LHCGR), 2p21 (thyroid adenoma associated protein; THADA) and 9q33.3 
(DENN/MADD domain containing 1A; DENND1A). Two of these loci, THADA and 
DENND1A have been confirmed as risk loci in a European PCOS cohort (NIH criteria) 
but there was insufficient power to confirm LHCGR as a risk locus [81]. A further 
GWAS has identified THADA as a novel Type 2 diabetes (T2DM) gene associated 
with pancreatic beta cell dysfunction [82]; this might explain in part the increased risk 
of T2DM observed in PCOS. 
16 
 
An important link between PCOS and obesity was demonstrated genetically for the first 
time by data from a case-control study in the United Kingdom that involved 463 
patients with PCOS and more than 1300 female controls [83]. This study showed an 
association between the FTO gene and obesity which was confirmed by meta-analysis 
of European and Chinese data [84, 85]. 
 
1.3.5     Prevalence 
PCOS is recognised as one of the most common endocrine and metabolic disorders in 
pre-menopausal women. Its prevalence depends in part on the diagnostic criteria used 
to define the disorder [86]. In the general population to date the prevalence of PCOS 
has been determined primarily using the NIH 1990 criteria. As per the NIH criteria the 
prevalence rates of PCOS have varied between 6 to 10% across the globe [86-90].  
However, an Oxford study conducted at the same time found prevalence rates of 
between 8% (using NIH criteria) and 26% (using polycystic ovaries on ultrasound and 
an additional feature of PCOS as diagnostic criteria) [88]. A number of conditions may 
be associated with an increased prevalence of PCOS such as oligo-ovulatory infertility 
[91], obesity and/or insulin resistance [92, 93], the presence of Type1 [94], Type 2 [95] 
or gestational diabetes mellitus [96], a history of premature adrenarche [97] and first 
degree relatives with PCOS [79, 98]. 
 
1.3.6 Clinical Features 
PCOS is an important cause of menstrual irregularity and androgen excess in women. 
As it is a syndrome with multiple potential aetiologies clinical presentations can be 
variable with key features of oligo or anovulation and hyperandrogenism.  Other 
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features are polycystic ovaries on pelvic ultrasonography, infertility due to 
oligoovulation, obesity, and insulin resistance. 
 
1.3.6.1   Reproductive 
PCOS is estimated to be the most common cause of ovulatory dysfunction, accounting 
for 70–90% of ovulatory disorders [99] . Prolonged periods of anovulation are likely 
associated with increased infertility [100]. Women with PCOS are also more likely to 
develop gestational diabetes in pregnancy and have a higher risk of pregnancy 
complications than controls [101]. Other factors associated with PCOS, such as obesity, 
have also been associated with subfertility and delayed conception [102]. 
 
1.3.6.2 Dermatological 
Hirsutism, acne and androgenic alopecia are the common features of hyperandrogenism 
in PCOS. Hirsutism is present in between 65 to 75% of subjects with PCOS [103], the 
prevalence of acne and male pattern balding varies between 14 to 25% [104]. 
Androgenic alopecia has been associated with metabolic syndrome [105] and insulin 
resistance [106, 107]. 
 
1.3.6.3 Metabolic 
Women with PCOS are commonly overweight or obese. Although the exact prevalence 
is not known, most investigators find that at least one-half of women with polycystic 
ovary syndrome  are obese [108]. Insulin resistance is common in PCOS with 
prevalence rates reported from 44 to 70% [63] and has been shown to be independent of 
obesity. In addition, the prevalence of the metabolic syndrome in women with PCOS 
appears to be increased [109, 110].  Most studies of women with PCOS have 
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demonstrated low high-density lipoprotein (HDL) cholesterol and high triglyceride 
concentrations, consistent with their insulin resistance [111], as well as an increase in 
low-density lipoprotein (LDL) cholesterol [112, 113]. Women with PCOS are more 
likely to have an increase in small dense LDL particles (associated with increased risk 
of cardiovascular disease) when compared to BMI matched women and insulin 
resistance without PCOS [114, 115]. There is increased risk of impaired glucose 
tolerance (IGT) and Type 2 Diabetes [61, 116, 117], especially in women with a first 
degree relative with type 2 diabetes with a reported 2.6 fold increase in prevalence 
[116]. In one study the annual conversion rate from normal glucose tolerance to 
impaired glucose tolerance was 17%. Obstructive sleep apnoea (OSA) has been found 
to be five- to thirty-times higher in women with PCOS compared to BMI-matched 
controls [118]. The prevalence of non alcoholic fatty liver disease (NAFLD), including 
non alcoholic steatohepatitis (NASH) may be increased in women with PCOS by 2% to 
70% depending on the diagnostic criteria used for PCOS, NAFLD and the presence of 
obesity [119-122].  
 
1.3.7 Morbidity associated with PCOS 
1.3.7.1 Cardiovascular Disease 
Obesity, hypertension, dyslipidaemia and T2DM are all risk factors for cardiovascular 
disease (CVD). It may appear that despite the high prevalence of risk factors for CVD 
in women with PCOS, there are limited longitudinal studies to definitively confirm an 
increased risk of CVD morbidity or mortality, and those undertaken are too small or 
have insufficient follow-up to detect differences in event rates [123]. Nevertheless, 
epidemiological data consistently point to increased cardiovascular risk in women with  
PCOS. The nurses’ health study, a prospective cohort study of 82,439 nurses with 14 
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years of follow-up, found a significantly increased risk of non-fatal or fatal coronary 
heart disease in women who had reported very irregular menstrual cycles (age-adjusted 
relative risk 1.67, 95% CI 1.35-2.06) which remained after adjustment for BMI and 
other confounding factors (multivariate risk ratio 1.53, 95% CI 1.24-1.90) [124]. 
Although there was no confirmed diagnosis of PCOS in these women, the commonest 
cause for irregular menstrual cycles is PCOS. In addition, a case-control study based on 
data in the Women’s Health Study database found that women who developed 
cardiovascular events had lower SHBG and higher calculated free androgen index 
[125]. Furthermore an evaluation of postmenopausal women for suspected ischaemia 
showed that clinical features of PCOS were associated with more angiographic 
coronary artery disease and worsening cardiovascular event-free survival [126]. A large 
community-based database review showed that women with PCOS did not have an 
increased risk of large vessel disease but there was an increased risk of T2DM 
compared to age and BMI-matched controls [127]. Therefore it appears that there are 
conflicting evidence with respect to cardiovascular risk. 
Studies exploring surrogate markers of cardiovascular disease studies have shown 
increased carotid artery intima-media thickness (an independent predictor of stroke and 
myocardial infarction) in women with PCOS compared with age-matched control 
women [128]. Coronary artery calcification, is more common in women with PCOS 
than in controls, even after adjusting for the effects of age and BMI [129, 130]. 
Echocardiographic changes in PCOS showed anatomic and functional differences such 
as increased left atrial size, increased left ventricular mass index, lower left ventricular 
ejection fraction [131] and diastolic dysfunction [132]. The left ventricular mass index 
was related to the degree of insulin resistance [131]. In addition some studies 
demonstrate impaired endothelial function in women with PCOS with features of 
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reduced brachial artery reactivity in response to hyperaemia [133, 134] and reduced 
vascular compliance. This has been demonstrated in women with PCOS at an early age 
(early 20’s) and largely independent of obesity, insulin resistance, total testosterone or 
total cholesterol [135]. A cross sectional study conducted by our group previously 
showed an association of increased central arterial stiffness and diastolic dysfunction 
with insulin resistance and central obesity but this was not associated with any increase 
in young women with PCOS per se [136]. Treatment with insulin sensitising drugs or 
weight loss has been associated with improvement in endothelial function although the 
results have been variable between study groups on account of the diagnostic criteria 
used and the heterogeneity of the study population [137-139]. 
 
1.3.7.2 Type 2 Diabetes Mellitus 
As mentioned above, there is an increased risk of developing T2DM in PCOS. Both 
adolescent and adult women with PCOS are at increased risk of developing Impaired 
Glucose Tolerance (IGT) as well as type 2 diabetes. A diagnosis of PCOS confers a 1.5 
to 2 fold increased risk of developing Type 2 diabetes [127]. The prevalence of IGT 
and type 2 diabetes in PCOS women varies up to 35 % and 10%, respectively 
depending on the criteria used for the diagnosis and the age, ethnicity and BMI of the 
population [108, 116, 140-142] . The rate of conversion from IGT to DM2 in 2 
Australian studies  ranged from 2.9% per year to 8.7% per year [143, 144]. Women 
with PCOS are also at a higher risk of developing gestational diabetes (GDM) 
independent of weight. However obesity can exacerbate the onset of GDM in PCOS 
[140, 143]. The International Diabetes Federation recognises PCOS as a non modifiable 
risk factor for the development of type 2 diabetes [145]. 
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As discussed earlier insulin resistance and beta cell dysfunction contribute to glucose 
intolerance which can progress to diabetes. Glucose intolerance develops when there is 
a defect in the secretion of insulin or on account of the pancreatic cells being unable to 
compensate for insulin resistance. The occurrence of hyperinsulinaemia and insulin 
resistance is found more frequently in women with PCOS compared with age and 
weight matched controls [146, 147]. Anovulatory women have a greater degree of 
insulin resistance than those with menstrual regularity [148, 149]. Insulin resistance has 
also been correlated with androgen levels in women with PCOS [150]. Insulin 
resistance is a precursor for type 2 diabetes and cardiovascular disease and hence these 
conditions occur more frequently in PCOS. Glucose intolerance is seen at an earlier age 
in the third to fourth decade of life [116, 140]. It has been observed that women with 
PCOS have increased mortality from complications of diabetes [151]. 
 
1.3.7.3  Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic 
Steatohepatitis (NASH) 
NAFLD is characterised by excessive fat accumulation in the liver (steatosis), whereas 
NASH defines a subgroup of NAFLD in which steatosis coexists with liver cell injury 
and inflammation (after exclusion of other causes of liver disease (viral, autoimmune, 
genetic, alcohol consumption, etc). NAFLD is now recognised as the leading cause of 
cryptogenic cirrhosis and encompasses a spectrum of diseases ranging from simple 
steatosis to nonalcoholic steatohepatitis (NASH) to cirrhosis [152, 153]. Insulin 
resistance is detected in up to 80% of cases of NAFLD and there is a near universal 
association between NAFLD and IR irrespective of obesity [154]. The first connection 
between NAFLD and PCOS was reported in 2005 and subsequent retrospective studies 
have confirmed this association [155]. The prevalence of NAFLD within the PCOS 
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population is now estimated to be anywhere between 15% and 55% depending on the 
diagnostic index used for PCOS and NAFLD (increased serum alanine 
aminotransferase or ultrasound) [120, 121, 156]. Risk factors pertinent to PCOS include 
increasing age, ethnicity, and metabolic dysfunction (obesity, hypertension, 
dyslipidaemia, diabetes). A systematic review determined that IR is present in 50%-
80% of women with both PCOS and NAFLD [157] and multiple studies have shown 
that PCOS women with hepatic steatosis have elevated levels of IR compared to PCOS 
women without steatosis [122, 156, 158]. It is not clear how androgens influence 
disease progression in NAFLD but one theory suggests suppression of LDLR gene 
transcription resulting in the downregulation of low density lipoprotein (LDL) receptor 
in women with PCOS which prolongs the half-life of very low-density lipoprotein 
(VLDL) and LDL and thus induce lipid accumulation in the liver [154]. Thus, women 
with PCOS and metabolic risk factors and/or IR may be screened using serum markers 
of liver dysfunction. If serum markers are elevated, noninvasive quantification of 
fibrosis by ultrasound and liver biopsy may be considered [159]. 
 
1.3.7.4 Obesity 
Many women with PCOS are overweight or obese (between 38% to 88%) [160, 161]. 
Increased abdominal obesity is associated with hyperandrogenaemia and increased 
metabolic risk [162]. 
The prevalence of obesity varies greatly across the world, yet the prevalence of PCOS 
remains relatively similar in studies in countries with different background rates of 
obesity (30% – 70%) [108, 163]. A modest but non-significant trend has been reported 
in the prevalence of PCOS with increasing obesity [93]. This may result due to the 
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combined effect of a genetic predisposition to obesity in the context of an obesogenic 
environment as a result of reduced exercise and poor diet. 
Abdominal obesity may cause relative hyperandrogenaemia, characterised by reduced 
SHBG (Sex Hormone Binding Globulin) and increased bioavailable androgens to target 
tissues [164]. This may be associated with an  increased rate of testosterone production 
and a non-SHBG-bound androgen production rate of dehydroepiandrosterone and 
androstenedione [165]. This might explain the increased frequency of menstrual 
abnormalities and chronic anovulation in adult overweight and obese women with 
PCOS compares to normal weight women [164]. In addition obese women with PCOS 
also exhibit diminished responsiveness to ovulation inducing drugs such as clomiphene 
citrate, gonadotrophins or pulsatile GnRH [100, 166]. 
Although weight gain in both normal women and those with PCOS is associated with 
increasing insulin resistance, most women with PCOS (between 50% and 90%, 
depending on the diagnostic criteria used) have insulin resistance to a significantly 
greater extent than in age and BMI-matched control women, with subjects  with higher 
BMIs showing a higher degree of insulin resistance [148, 167].  
The presence of obesity in PCOS increases the risk of metabolic syndrome, Impaired 
glucose tolerance / diabetes mellitus, dyslipidaemia and insulin resistance [116, 140, 
148, 164]. 
 
1.3.7.5   Depression 
An increased prevalence of depression has been consistently observed in women with 
PCOS in small community based and case control studies. Most of these studies are 
limited by sample size and in some cases lack of control subjects. In women with 
PCOS compared with non-BMI-matched controls, self-rated questionnaires 
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demonstrate an increased rate of depressive symptoms [168, 169]. In studies with direct 
psychiatric interviews, there was a higher lifetime incidence of a major depression 
episode and recurrent depression (OR, 3.8; 95% CI, 1.5– 8.7; P= .001) and a history of 
suicide attempts that was seven times higher in PCOS cases compared to controls 
[170]. A U.S. study reported a 50% rate of depression in women with PCOS (n =32). 
However, there were no control subjects included in the study. Using the Centre for 
Epidemiological Studies Depression Rating Scale, the investigators found higher scores 
among women with insulin resistance and in women with elevated body mass index 
(BMI). This is supported by another study by Holinrake et al.which showed that 
women with PCOS were at an increased risk for depressive disorders (new cases) 
compared with controls (21% vs. 3%; odds ratio 5.11 [95% confidence interval (CI) 
1.26–20.69]; P=.03). This was noted to be independent of obesity or infertility: subjects 
with PCOS and depression had a higher BMI and insulin resistance (P<0.02) [171]. The 
relationship between androgens and mood in women is controversial. Although a few 
small studies suggest a correlation between depressive symptoms and serum androgens 
[168, 172] other studies have failed to demonstrate this association [173]. 
 
1.3.7.6  Sleep Disordered Breathing (SDB) / Obstructive Sleep Apnoea (OSA) 
Women with PCOS develop OSA at rates that equal or exceed those in men. The high 
prevalence of OSA is thought to be a function of hyperandrogenism as well as obesity 
(common in PCOS), although these factors alone do not fully account for the finding 
[118, 174]. Insulin resistance may be a stronger risk factor than obesity or testosterone 
for sleep disordered breathing [118]. Women with PCOS were 30 times more likely to 
have SDB independent of obesity, the use of oral contraceptives seems to protect from 
SDB. [118]. Oestrogen suppresses IL-6 secretion, which is elevated in sleep apnoea, 
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potentiates the transcription of the corticotrophin-releasing hormone (CRH) gene, and 
stimulates the noradrenergic system in the brain by inhibiting norepinephrine clearance 
[175, 176]. 
 
1.3.7.7 Cognitive Function 
There is no clear evidence to suggest an adverse effect of PCOS on cognitive function. 
There are very few studies which have investigated this, these studies have been limited 
by the lack of adequately matched controls as well as sample size. In a study by 
Barnard et al. who compared neuropsychological functioning in an internet-based study 
in 135 women with PCOS and 322 controls, women with PCOS demonstrated impaired 
performance in terms of speed and accuracy, on reaction time and word recognition 
tasks [177]. Some studies have investigated the effects of manipulation of testosterone 
on cognition in women with PCOS [178]. A decrease in free testosterone levels did not 
affect performance on tests of visuospatial ability, verbal memory, manual dexterity, or 
perceptual speed. However there was an improvement in measures of verbal fluency 
compared to their pre-treatment scores. One study evaluated working memory function 
with the use of functional magnetic resonance imaging before and after anti-androgenic 
treatment in women with PCOS [179]. This study showed an improvement in measures 
of executive function with anti-androgen therapy with normalisation of activation of 
brain centres associated with a working memory task.   
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1.4 MAGNETIC RESONANCE IMAGING 
 
1.4.1 Introduction 
Magnetic Resonance Imaging (MRI) is a commonly used non invasive radiological 
imaging technique that produces three dimensional detailed anatomical images without 
the use of damaging radiation. It is often used for disease detection, diagnosis, and 
treatment monitoring. The use of MRI scanners are dependent on use of strong 
magnetic fields, radio waves and field gradients to form images of the body. Due to the 
absence of ionising radiation in MRI as opposed to computerised tomography (CT), this 
has become one of the most commonly used imaging technique for the evaluation and 
diagnosis of  medical conditions, staging and follow up  of disease.  
 
1.4.2 Principles of MRI 
 
MRI is based on the principles of nuclear magnetic resonance of certain atomic nuclei. 
Protons as in a hydrogen nucleus are present in water molecules and hence in all body 
tissues. When a human body is placed in a strong magnetic field hydrogen nuclei 
behave as magnetic dipoles and partially align themselves in the direction of the 
magnetic field. Through manipulations of static and dynamic magnetic fields and use of 
radio-frequency pulses signals can be received and localised from protons anywhere in 
the body. These signals are then converted into digital images which characterise the 
signal from each ‘voxel’ (volume element) of the image.  
 
1.4.3 Diffusion Tensor Imaging 
 
The broad spectrum of magnetic resonance contrast mechanisms makes MRI one of the 
most powerful and flexible imaging tools for diagnosis in the central nervous system. 
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The advent of echo planar imaging (EPI)[180] significantly shortened magnetic 
resonance imaging times. EPI allows acquisition of images in 20-100 msec. This time 
resolution virtually eliminates motion related artefacts. Echo planar images, with 
resolution and contrast similar to those of conventional MR images, can be obtained by 
using multishot acquisitions in only a few seconds. The most prevalent clinical 
application of EPI is imaging of the brain (Diffusion and functional MRI). 
Diffusion MRI is a magnetic resonance imaging method which allows the mapping of 
the diffusion process of molecules, mainly water, in biological tissues in vivo and non-
invasively. Molecular diffusion in tissues is not free, but reflects interactions with many 
obstacles, such as macromolecules, fibres, and membranes. Water molecule diffusion 
patterns can therefore reveal microscopic details about normal tissue architecture and 
the way that it is altered in disease. For most fluids and solid homogeneous materials 
like gels diffusion is the same in all directions. This diffusion pattern is described as 
isotropic (Fig 1.3A) where molecular motion is random and can be characterised by a 
single diffusion coefficient (diffusion coefficient is equal in whatever direction it is 
measured in). However in biological tissues diffusion is often anisotropic and therefore 
multiple coefficients are required to characterise it. This property is known as 
anisotropy (Fig 1.3B); it may be used to define the direction of the axons in a 
particular voxel.  
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                   A      B 
Fig 1.3 Drawings showing diffusion of water molecules    
A) Isotropic diffusion showing random diffusion of water molecules in liquids  
B) Anisotropic diffusion as seen in strongly aligned white matter fibres where random motion is 
constrained by physical barriers such as cell membranes 
 
Using conventional MRI, grey matter of the brain can be easily identified. However 
with conventional proton magnetic resonance imaging techniques, the white matter of 
the brain appears homogeneous without any suggestion of the complex arrangements of 
fibre tracts. Hence the demonstration of anisotropic diffusion in the brain by magnetic 
resonance has demonstrated a means of non-invasive exploration of the structural white 
matter in vivo [181-183].  
                                          
Fig 1.4 Axial tractographic image (2 dimensional image) created demonstrates white matter tracts in the 
brain in the left to right (red), anterior to posterior (green) and superior to inferior (blue) directions. 
 
This orientation of fibre bundles can be visualised on 2 dimensional images by 
assigning a colour to each of the 3 axes, left to right (red) anteroposterior (green) and 
superior to inferior (blue) (Fig 1.4) [184, 185]. These colour maps are very useful for 
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surveying the organisation of white matter in the brain and for identifying major white 
matter tracts on 2 dimensional sections [185, 186]. 
In tissues, such as brain grey matter, where the measured apparent diffusivity is largely 
independent of the orientation of the tissue (i.e. isotropic), it is usually sufficient to 
characterize the diffusion characteristics with a single (scalar) apparent diffusion 
coefficient (ADC). White  matter  is highly  anisotropic  owing to  parallel  orientation  
of its nerve fibre tracts and diffusion is restricted perpendicular to the long axis of the 
nerve fibres [187]. As the measured diffusivity is known to depend upon the orientation 
of the tissue, no single ADC can characterise the orientation-dependent water mobility 
in these tissues. The next most complex model of diffusion that can describe 
anisotropic diffusion is to replace the scalar diffusion coefficient with a symmetric 
effective or apparent diffusion tensor of water, D which is a mathematical tool for 
representing diffusion in 3D and describes the mobility of the molecules in each 
direction and the correlation between these directions [188]. The diffusion tensor model 
consists of a 3 × 3 matrix derived from diffusivity measurements in atleast six collinear 
directions [189, 190]. The tensor matrix is diagonally symmetric. 
 
             Dxx  Dxy  Dxz 
 
D   =     Dyx  Dyy   Dyz 
 
             Dzx  Dzy  Dzz 
The three diagonal elements (Dxx, Dyy, Dzz) represent diffusion coefficients measured 
along each of the principal (x, y and z) laboratory axes. The six off-diagonal terms 
(Dxy, Dyz, etc) reflect the correlation of random motions between each pair of 
principal directions. 
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Fig 1.5 Fibre tracts have an arbitrary orientation with respect to scanner geometry (x, y, z axes) and 
impose directional dependence (anisotropy) on diffusion measurements. 
  
A diffusion tensor representing these three principal axes of diffusion can be visualised   
as an ellipsoid whose diameter in any direction  estimates the diffusion of water 
molecules in that direction in each voxel in the brain (fig 1.6). The ellipsoid itself has a 
long axis and two more small axes that describe its width and depth. All three of these 
are perpendicular to each other and cross at the centre point of the ellipsoid. The axes in 
this setting are called eigenvectors and the magnitude of their diffusion eigenvalues. 
 
Fig 1.6  Diffusion Ellipsoid The three-dimensional diffusivity is modelled as an ellipsoid whose 
orientation is characterized by three eigenvectors (ϵ1, ϵ2, ϵ3) and whose shape is characterized three 
eigenvalues (λ1, λ2, λ3). The eigenvectors represent the major, medium, and minor principle axes of the 
ellipsoid, and the eigenvalues represent the diffusivities in these three directions, respectively. 
The eigenvector corresponding to the largest eigenvalue, termed the principal 
eigenvector, corresponds to the main direction of diffusion of water molecules in that 
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voxel. By convention eigenvalues are labelled in descending order of magnitude (ƛ1 ≥ 
ƛ2 ≥ ƛ3). Another important measure is the tensor orientation described by the major 
eigenvector direction. With reference to figure 1.6, when the principal eigenvalue is 
much larger than the second and third eigenvalues, anisotropy measures will be high, 
indicating a preferred direction of diffusion. This corresponds to a cigar or prolate 
shape of a diffusion ellipsoid. The preferred direction of diffusion is indicated by the 
long axis of the ellipsoid or by the primary eigenvector of the tensor. This pattern of 
diffusion within a voxel is found in parts of the brain with densely packed parallel 
fibres. 
1.4.4 Diffusion Metrics 
The display, meaningful measurement, and interpretation of 3D image data with a 3×3 
diffusion matrix at each voxel is a challenging task. In order to simplify data the image 
information is distilled into simpler scalar maps. The two most common measures are 
the trace and anisotropy of the diffusion tensor. The trace of the tensor (Tr), or sum of 
the diagonal elements of D, is a measure of the magnitude of diffusion and is 
rotationally invariant. 
Trace of the tensor (Tr) = ƛ1 + ƛ2 + ƛ3 
The mean diffusivity (MD) is used in many published studies and is simply the trace 
divided by three which is equivalent to the average of the eigenvalues. 
Mean Diffusivity (MD) = ƛ1 + ƛ2 + ƛ3 
      3 
Another important measure of the directionality of diffusion commonly employed in 
diffusion MRI studies is the fractional anisotropy (FA) described originally by Basser 
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and Pierpaoli [191]. It is a scalar value that describes the degree of anisotropy of a 
diffusion process. FA values vary between a value of 0 indicating isotropic diffusion 
(cerebrospinal fluid and grey matter) to a maximum value of 1 indicating perfectly 
linear diffusion along the principal eigenvector (highest in major white matter tracts).                   
It is independent of local fibre orientation and is therefore a relatively objective and 
easy measure to compare across subjects. It can also be computed in each individual 
voxel. FA is high in white matter, especially in major tracts in which axons are packed 
in a coherent, parallel fashion. It is also increased by the presence of axonal membranes 
or myelin sheaths that hinder diffusion. Disruption of this coherent organisation or loss 
of axons or myelin generally leads to a decrease in FA and increase in MD. A decline 
in FA is often used as an index of decreasing white matter health.  
The measure of diffusion along the principal axis ƛ1 is called the axial diffusivity (AD) 
and is assumed to reflect the orientation of fibres in a white matter tract (measure of 
axonal integrity).  
Radial diffusivity (RD) is a measure of diffusion perpendicular to the principal axis 
(This is the average of the diffusivities in the two minor axes ƛ2 and ƛ3).  
Radial Diffusivity (RD) = ƛ2 + ƛ3 
                                     2 
RD is an assessment of the degree of restriction due to membranes [192].  
As mentioned earlier FA measures between a value of 0 indicating isotropic diffusion 
(cerebrospinal fluid and grey matter) to a maximum value of 1 indicating perfectly 
linear diffusion along the principal eigenvector (highest in major white matter tracts).                   
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The use of diffusion tensor imaging (DTI) has significantly improved the imaging and 
interpretation of diffusion of water molecules in tissues with direct in vivo examination 
of aspects of tissue microstructure. The principles of diffusion anisotropy are adopted to 
provide excellent details of white matter microstructure and the construction of white 
matter tracts. (Tractography) [193].  
1.4.5 White Matter Tractography      
With the use of diffusion tensor fibre tracking the diffusion tensor of each voxel can be 
utilised to follow an axonal tract in 3D from voxel to voxel through the human brain. 
This follows coherent spatial patterns in the major eigenvectors of the diffusion tensor 
field [194, 195]. This principle is often combined with functional or anatomic 
information to delineate specific white matter pathways [194]. White matter patterns 
are estimated by starting at a specified location (also called the ‘seed’ point), estimating 
the direction of propagation (major eigenvector), and moving a small distance in that 
direction (called tract integration). The tract direction is then re-evaluated and a further 
step is taken until the tract is terminated. 
                                         
Fig 1.7 Schematic diagram showing a basic algorithm for tract reconstruction  
Degree of diffusion anisotropy is indicated by gray scale (white is highest). On basis of defined 
thresholds, tracking (long curved arrows) is along voxels with similar measures of anisotropy and 
direction of principal eigenvector. Asterisks indicate starting point of tracking. 
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This principle is illustrated above in Fig 1.7 where average fibre orientation is 
estimated from diffusion anisotropy at each pixel (ellipsoids in neighbouring voxels 
line up), and a line is propagated from a pixel of interest (pixels with asterisks) 
following the fibre orientation until it reaches a brain region of low anisotropy which is 
depicted by the dark pixels. 
There is good evidence that tracking results of prominent white matter tracts correlate 
well with classical definitions based on post mortem studies [196, 197]. On the other 
hand the technique can produce false positives and false negative results due to noise, 
partial volume effects, and complex fibre architectures within a pixel [198, 199]. This 
can be improved upon by applying anatomical constraints by employing multiple 
regions of interest (ROI) [197, 200].  This technique requires a priori knowledge about 
the trajectory and can be used only for well-characterised white matter tracts. Although 
this improves the validity of the technique it is unlikely to be fully accurate. 
Development of robust protocols by devising specific region of interest drawing 
schemes based on the anatomical features of individual tracts and using regions that are 
sufficiently large has improved reproducibility to a significant degree. This has 
developed as a valuable tool to test hypotheses whether specific white matter tracts are 
involved in a disease of interest. 
Although tractography corresponds well to classic neuroanatomy, problems of 
validation remain as to the degree to which results differ from those of anatomic 
methods such as dissection [201]. Nevertheless this divergence would not diminish its 
utility as this form of 3D tractography can depict human neuroanatomy non-invasively, 
at the same time can detect changes to anatomy and microstructural integrity of specific 
white matter pathways. Microstructural abnormalities in several white matter tracts is 
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increasingly being recognised as a mechanism of cognitive deterioration in aging and 
metabolic studies [202-204].  
  
Fig 1.8 Whole brain Tractography – Axial view (Left) and sagittal view (Right) Image generated 
from whole brain diffusion tensor tractography using EXPLORE-DTI software. Direction of white 
matter  fibres  are  illustrated : Anterior  to  Posterior (green),  Left  to  Right (red)  and  Superior to 
Inferior (blue) 
 
1.4.6 Tract Based Spatial Statistics (TBSS) 
Tract-based spatial statistics (TBSS) is an automated observer-independent approach 
for assessing groupwise microstructural differences in the major white matter pathways 
of the brain [205]. It enables voxel-wise and group-wise comparision of diffusion 
parameters across all major white matter tracts common to subjects without the need for 
a prespecified region of interest. 
As mentioned earlier there are several limitations to white matter tractography. This 
method is subjective and restricts the areas of investigation to those that are either 
easily identifiable or thought to be of greatest clinical significance and therefore may 
miss unexpected areas of injury. ROI-based analyses can be time consuming and often 
rely on investigator accuracy. These limitations make comparison of multiple brain 
regions across larger groups more difficult. In contrast, an important advantage of 
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TBSS is that it is free of a priori bias about the likely location of structural alteration in 
the brain. TBSS is a widely accepted approach for statistical analysis of diffusion data. 
This  process  is  done  through  linear  and  non-linear  alignment , thus  improving 
interpretability of analysis of multi-subject DTI data investigation of the brain as a 
whole and not specific white matter tracts. As TBSS is fully automated it is simple to 
apply and investigates the whole brain. TBSS is achieved first by taking the average of 
all the FA values of major white matter tracts as FA skeleton and then by projecting all 
the images of subjects to this FA skeleton. This will be explained in detail in Chapter 2. 
1.4.7 Thesis Aims 
PCOS is a common endocrine disorder of young women characterised by abnormalities 
in both reproductive and metabolic health. This is associated with an increased risk of 
metabolic risk factors such as type 2 diabetes, obesity and dyslipidaemia. There is 
evidence to suggest that these risk states may have an influence on brain structure and 
function. Both type 1 and type 2 diabetes are associated with altered microstructural 
measures derived from diffusion tensor MRI [202] [206]. Several studies have now 
shown associations between BMI and white matter microstructure [203, 207]. 
Alterations in white matter microstructure has been found to correlate with cognitive 
performance in type 2 diabetes [202]. It is unclear which of these factors are critical in 
influencing brain structure and function as these metabolic features occur in clustered 
syndromes rather than as isolated abnormalities. This is also true of previous cognitive 
studies in PCOS that might have confounded by BMI [208].  
We hypothesise that young insulin resistant women with PCOS are at risk of early 
subtle deficits in cognition and microstructural alteration in the brain.  
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The aim of this study is to establish whether young women with PCOS display altered 
white matter microstructure and cognitive function by using advanced MRI and a series 
of validated measures of cognition. 
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CHAPTER 2:  METHODS 
 
2.1  Outline of Study 
 
2.1.1  Study Approval 
 
The study was approved by the Research and Development department at the 
University Hospital of Wales (UHW) (Ref 08/RPM/4276) and the South East Wales 
Research Ethics Committee (Ref 08/WSE04/53) following international guidelines on 
Human subjects research protection (Declaration of Helsinki). The study was sponsored 
by Cardiff University (CU) (Ref SPON CU 523 - 08). 
 
2.1.2  Recruitment 
 
Patients aged between 18 and 45 years of age were recruited from local endocrinology, 
dermatology and  gynaecology  clinics.  They were provided with an information sheet 
giving details about the study. The initial contact was followed up with a telephone call 
to determine interest and confirm eligibility. Healthy volunteers aged between 18 and 
45 years, were recruited from UHW and CU using intranet postings. All interested, 
eligible women were telephoned a week later to determine if they wished to participate 
or not. 
 
2.1.3  Inclusion and Exclusion Criteria of Study Participants 
 
 
Patients with a diagnosis of PCOS were recruited from the endocrine clinic at UHW. 
Diagnosis was according to the Rotterdam criteria [49]. Congenital adrenal hyperplasia,  
Cushing’s syndrome, androgen-secreting tumours, hyperprolactinaemia and thyroid 
dysfunction were excluded by biochemical testing. Women were excluded from 
participation if they were pregnant, breastfeeding or if they had a history of diabetes, 
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hypertension or hyperlipidaemia. Potential participants who were taking anti-
hypertensive agents, lipid-lowering agents, glucose lowering  agents,  weight  reducing   
agents or glucocorticoids and  who had used anti-androgens within 6 months were also 
excluded. Neurological exclusion criteria included previous or current major 
psychiatric illness, clinical cerebrovascular disease, previous severe head injury, current 
substance and alcohol abuse. 
 
Healthy volunteers were recruited as controls with 1 to1 matching for age and BMI. For 
each individual patient, a control was identified matched for age (within 2 years) and 
BMI (within 2kg/m²). Controls needed to have regular menstrual cycles (menses every 
27-32 days). Control subjects with signs of hirsutism or with a personal history of 
diabetes or hypertension, or a family history of PCOS were excluded. Their health 
status was determined by history, physical examination and hormonal evaluation 
(testosterone, androstenedione, thyroid function, prolactin and 17-hydroxyprogesterone. 
All women were investigated during the follicular phase of their menstrual cycle. 
 
2.1.4 Consent 
 
 
All participants gave written informed consent prior to entering the study. 
 
 
2.1.5 Protocol 
 
Participants attended the Clinical Research Facility (CRF), UHW at 8 am following an 
overnight fast. All subjects had a pregnancy test (urine β-HCG) to confirm that they 
were not pregnant before a clinical assessment, venepuncture and oral glucose tolerance 
test were undertaken. The information acquired was recorded on case report forms. 
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2.2 Clinical Assessment 
 
2.2.1 History and Examination 
 
Details of past medical history, medication taken currently, contraceptive use, smoking  
 
history,  family  history and  menstrual  history  were  recorded.  A routine   physical  
 
examination was performed. 
 
 
2.2.2 Blood Pressure Measurement 
 
After ten minutes of rest in a seated position, three blood pressure recordings were taken  
from  the  right  brachial  artery using  a validated semi-automated  oscillometric  
device (Omron 7051T; Omron Corporation, Tokyo, Japan). An average of three 
readings taken over a 10-minute period was recorded. 
 
2.3 Biochemical and Metabolic Measurements 
 
 
2.3.1 Sample Collection and Storage 
 
 
With the subject at rest, an intravenous cannula or butterfly needle was inserted into a 
suitable vein in the antecubital fossa or forearm and secured. Blood was collected 
directly via a vacutainer or via a syringe and then decanted into blood bottles. The 
cannula or butterfly needle was then flushed with 5 ml of normal saline. The subject 
then received a drink containing 113 ml of Polycal® (concentrated carbohydrate) with 
187 ml of water.  This provides an equivalent carbohydrate load to a standard 75g dose 
of anhydrous glucose. Samples were taken at 30, 60, 90 and 120 minutes and marked 
with the subject number and time. The first 5 ml of blood at each collection were 
discarded and the cannula was flushed with 5 ml of normal saline after the sampling 
was completed. The cannula or butterfly needle was removed after the 120 minutes 
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sample was taken. Samples were centrifuged at 4000 rpm for 8 minutes and stored at -
30°C prior to analysis. 
 
2.3.2 Assays 
 
Serum total cholesterol, high density lipoprotein cholesterol (HDL) and triglycerides 
were assayed using an Aeroset automated analyser (Abbott Diagnostics, 
Berkshire,UK); LDL cholesterol (LDL) was calculated using Friedewald’s formula. 
Insulin was measured using an immunometric assay specific for human insulin 
(Invitron,Monmouth, UK) and glucose was measured using the Aeroset chemistry 
system (Abbott Diagnostics, Berkshire, UK). High sensitivity C-reactive protein 
(hsCRP) was assayed by nephelometry (BN™ II system, Dade Behring, Milton 
Keynes, UK) and total testosterone was measured by liquid chromatography-tandem 
mass spectrometry (Quattro™ Premier XE triple quadruple tandem mass spectrometer, 
Waters Ltd, Watford, UK). Androstenedione was measured by immunoassay [Siemens 
Healthcare]. The interassay coefficients of variation were all less than 9%. 
 
2.3.3 Estimations of Insulin Sensitivity and Insulin Resistance 
 
The hyperinsulinaemic-euglycaemic clamp is the gold standard method to measure 
insulin sensitivity [209]. The main advantage of this method is that whole body glucose 
disposal is measured directly at a defined level of hyperinsulinaemia. However, the 
method is labour intensive, time consuming and expensive and for these reasons was 
not used. 
Two well described alternative methods have been established to overcome the 
limitations of the hyperinsulinaemic-euglycaemic clamp. These are the homeostatic 
model assessment (HOMA) [210] and the quantitative insulin sensitivity check index 
(QUICKI) [211]. HOMA-IR is a paradigm model derived from a mathematical 
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assessment of the interaction between β-cell function and IR and is calculated using the 
formula: 
HOMA-IR = (FPI x FPG)/22.5 
 
where FPI = fasting plasma insulin (mU/l) and FPG = fasting plasma glucose (mmol/l). 
QUICKI uses a log transform of the insulin-glucose product and therefore correlates to 
HOMA-IR. These methods require a single fasting insulin and fasting glucose 
measurement and are therefore ideal for studies involving large numbers of subjects. 
HOMA-IR was used in this study for these reasons and because it correlates highly 
(Rs=0.88, P<0.0001) with the hyperinsulinaemic-euglycaemic clamp [210]. The above 
methods do not measure insulin sensitivity in a dynamic state.  An OGTT assessment of 
glucose tolerance and insulin secretion in response to a glucose challenge was therefore 
also undertaken. Insulin measurements at 0, 30, 60, 90 and 120 minutes after a 75 gram 
glucose challenge allow calculation of area under curve (AUC) for insulin and glucose. 
The AUC insulin will be greater in an insulin resistant subject than a normal subject, as 
more insulin will be secreted in response to the glucose load. This is clinically 
important and has been associated with cardiovascular mortality [212]. Post-challenge 
insulin levels have also been shown to improve the performance of visceral fat 
adiposity in identifying subjects with metabolic disease [213]. 
 
2.4 Body Composition Measurements 
 
 
2.4.1 Anthropometric Measurements 
 
 
Height was measured to the nearest 0.1 centimetre (cm) using a stadiometer and 
recorded in metres (m). Measurements were taken with the subject’s footwear removed. 
Their head, back, buttocks and heels were placed against the wall and they were asked 
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to look straight ahead. The headboard was then moved until firmly pushing on the 
vertex. Weight was measured to the nearest 0.5 kilogram using digital weighing scales 
(Omron Monitor BF500, Omron Corporation, Japan). Subjects wore light clothing and 
had footwear removed. Body Mass Index (BMI) was calculated as weight (kg) divided 
by height (m) squared. Waist circumference was measured at minimal respiration to the 
nearest 0.5 cm by positioning a tape parallel to the floor and immediately above the 
superior iliac crests. Hip circumference was measured to the nearest 0.5 cm by 
positioning a tape parallel to the floor and at the greatest protrusion of the buttocks. 
 
 
2.4.2 Computed Tomography 
 
 
Computed tomography was carried out by Dr. Helen Blundell in the Nuclear Physics 
department at the University hospital of Wales. With the subject in the supine position, 
one cross-sectional scan was obtained by CT (Hawkeye, GE Medical Systems) using 
standard acquisition parameters (140kV,2.5mA, 10mm slice width, 13.6 s rotation time, 
2562 pixel matrix) at the level of the fourth and fifth lumbar spines. The image was 
imported into MATLAB (MathsWorks) and was analysed by Dr Blundell. The image 
was segmented into areas of non-adipose tissue and adipose tissue using a fixed range 
of CT numbers (-120 to -80 to represent fat) derived from a previously published study 
[214]. The visceral adipose tissue area and total adipose tissue areas were calculated by 
segmenting an intra-peritoneal region and the whole image respectively as shown in 
Figure 2.1. Subcutaneous adipose tissue area was calculated by subtracting the visceral 
fat area from the total fat area. 
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Fig 2.1 A single cross sectional CT scan image obtained at level of fourth and fifth lumbar spine with 
visceral adipose tissue area and total adipose tissue area calculated by segmentation of intra-peritoneal 
region which is illustrated enclosed within the yellow line. 
 
2.5 Cognitive Testing 
A set of cognitive tests was devised based on previous literature on cognitive 
dysfunction in metabolic disorders [23, 215]. Test domains assessed were episodic 
memory, attentional and executive function. All the cognitive tests were conducted at 
Cardiff University Brain Research Imaging Centre (CUBRIC). Participants were 
subjected to the initial screening process for imaging and following successful 
completion performed a battery of tests lasting between one and a half to two hours for 
each subject. The initial process of cognitive testing for the first three participants was 
carried out by Dr Claudia-Mettzler Baddeley, consultant neuropsychologist based at the 
School of Psychology, Cardiff University. Subsequent cognitive testing was carried out 
by myself initially under supervision of Dr Baddeley for the next three participants. I 
carried out independent cognitive assessments for the rest of the study. 
 
 
                                              Figure 2.1 Cross sectional CT scan image 
 
                                                 Intraperitoneal region enclosed within yellow line 
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2.5.1 Assessment of Premorbid IQ 
This was estimated with the National Adult Reading Test (NART , British Edition 
1982). It is a widely adopted method for estimating premorbid intelligence both for 
clinical and research purposes. The test requires subjects to read out loud a set of 50 
words, the pronunciations of which are irregular so have to be learnt and cannot be 
inferred from the spellings [216]. The responses are individually scored as correct or 
incorrect, according to their pronunciation. This score can then be used to derive a 
premorbid IQ estimate. This test is a measure of early learning and peak attainment. 
 
2.5.2   Assessment of Intelligence and Executive function 
 
2.5.2.1 Digit Span Task 
 
The Digit Span Task exercises short term and verbal working memory.  A series of 
digits (e.g., '8, 2, 4') were read out to the participants at one digit per second and were 
told to immediately repeat them back in the same order .If they did this successfully, 
they were given a longer list (e.g., '9, 2, 4, 1'). Participants got 2 attempts at each span. 
The test begins with two to three numbers, increasing until the participant fails both 
trials at a given length. Recognizable patterns (for example 2, 4, 6, 8) were avoided. At 
the end of a sequence, the person being tested is asked to recall the items in order. The 
average digit span for normal adults without error is seven plus or minus two. The 
length of the longest list a person can remember is that person's digit span. While the 
participant is asked to call out  the digits in the given order in the forward digit-span 
task, in the backward digit-span task the procedure is largely the same, except that 
subjects being tested are asked to recall the digits in backward order (e.g., if presented 
with the following string of numbers "3 7 9 1 5" the subject would be asked to recall 
the digits in reverse order; in this case, the correct response would be "5 1 9 7 3"). This 
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is a test of working memory as the participant has to hold and manipulate the digits 
‘online’ [217]. 
 
2.5.2.2 Digit Symbol Substitution Test (DST) 
  
 
Digit symbol substitutuion test is a neuropsychological test which measures response 
speed and focussed attention and is a sensitive indicator of brain damage, dementia age 
and depression. It consists of (e.g. nine) digit-symbol pairs followed by a list of 
digits. Under each digit the subject should write down the corresponding symbol as fast 
as possible. The number of correct symbols within the allowed time (120 sec) is 
measured. (Fig 2.2) 
 
 
 
Figure 2.2 Digit symbol substitution Test  
Nine digit symbol pairs followed by list of digits. The number of correct symbols obtained to each 
corresponding number in 120 seconds is measured. 
 
 
2.5.2.3 Verbal Trails Test 
 
Attention switching was examined with a version of the Verbal Trails Test that required 
alternation between letters and digits [218].  Subjects were asked to perform four tasks 
starting with a presentation of 50 digits in numerical sequence printed on a sheet of 
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paper. The amount of time required to verbally count numbers starting from 12 to 61 
was measured. The second task was similar to the first task but consisted of a list of 50 
letters with the subjects having to verbally start from the letter G through a sequence of 
50 letters up to the letter D. The third and fourth task consisted of retrieval and 
recitation of letters and numbers in alternation (digit-letter switching such as “28 D 29 
E 30 F31 G32 H up to 25 characters and letter-digit switching for example “R 13 S 14 
T 15 U 16 V17” up to a total of 25 characters. The time taken for each of the above 
tasks was measured. The amount of time in seconds measured as the sum of the time 
taken for task one and two subtracted from the sum of the time taken for task three and 
four was called the Verbal trails “switching cost”. Similarly the Verbal trails “errors” 
was calculated as the sum of the total errors measured in the four tasks. 
 
2.5.2.4 Verbal Fluency Test 
 
The Verbal  Fluency  Test  [219] consists of  two  tasks : category  fluency (sometimes 
called semantic fluency)  and  letter  fluency (sometimes called phonemic fluency). As 
per the standard versions of the tasks, participants were given 1 min to produce as many 
unique words as possible within a semantic category (category fluency) or starting with 
a given letter (letter fluency). The categories selected were Animals and Boy’s names 
and letters selected were F, A and S. The participant's score in each task is the number 
of unique correct words. 
 
2.5.2.5 Stroop Colour Word Test 
 
The suppression of response incongruent information was measured with the Stroop 
test. [220] The Stroop effect is a demonstration of interference in the reaction time of a 
task. When the name of a colour (e.g., "blue", "green", or "red") is printed in a colour 
not denoted by the name (e.g.,the word "red" printed in blue ink instead of red ink), 
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naming the colour of the word takes longer and is more prone to errors than when the 
colour of the ink matches the name of the colour. This test is considered to 
measure selective attention, cognitive flexibility and processing speed, and it is used as 
a tool in the evaluation of executive functions. 
 
2.5.2.6 Free and Cued Selective Reminding Test 
 
 
The 16-item version of controlled learning is called the Free and Cued Selective 
reminding Test (FCSRT) [221]. It has been used in several other longitudinal aging 
studies in North America and Europe to identify preclinical and early dementia. The 
test begins with a study phase in which subjects were asked to examine a card 
containing sixteen words (objects) for an item that goes with a unique category cue. 
The card was then taken away from the subject after one minute and immediate recall 
of the sixteen words was tested. The study phase was followed by the test phase that 
consisted of three recall trials, each preceded by 20 seconds of subjects counting 
backward to prevent recall from short-term memory. Each recall trial consisted of two 
parts. First, each subject had up to two minutes to freely recall as many items as 
possible. Next, aurally presented category cues were provided for items not retrieved by 
free recall. If subjects failed to retrieve the item with the category cue, they were 
reminded by presenting the cue and the item together. The sum of free and cued recall 
is total recall. The total score obtained from the three recall trials was a maximum of 48 
with a maximum score of 16 points per trial. 
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2.5.2.7 The Rey–Osterrieth Complex Figure Test (ROCF)  
 
 
The ROCF test is a neuropsychological assessment in which examinees are asked to 
reproduce a complicated line drawing, first by copying it freehand (recognition), and 
then drawing from memory (recall) [222]. It permits the evaluation of different 
functions, such as visuospatial abilities, memory, attention, planning, and  working 
memory (executive functions). 
The ROCF test consists of the following steps: 
Copy: In the Copy condition, the subject is given a piece of paper and a pencil, and the 
stimulus figure is placed in front of them. They reproduce the figure to the best of their 
ability. The test is not timed, but the length of time needed to copy the figure is 
observed. Once the copy is complete, the stimulus figure and the examinee's copy are 
removed from view. 
Immediate recall: After a short delay (2 minutes), the subject is asked to reproduce the 
figure from memory. 
Delayed recall: After a period of 20 minutes, the subject is asked once again to 
reproduce the figure from memory. In this study the delayed recall component of the 
test was not administered. 
 
2.5.2.8 Wechsler Abbreviated Scale of Intelligence – Second Edition (WASI-II) 
 
 
WASI-II provides a brief, reliable measure of cognitive ability for use in clinical, 
educational, and research settings. This form has four subsets (vocabulary, similarities, 
Block design and matrix reasoning), two composite scores (verbal and performance) 
and a full scale IQ. These tests have shown to be correlated strongly with general 
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intellectual functioning. Specifically, the subtests of vocabulary and similarities   are 
used to estimate verbal IQ (VIQ) which provides a measure of verbal comprehension 
and working memory, whereas block design and matrix reasoning are used to estimate 
performance IQ (PIQ) which provides a measure of perceptual organisation and 
processing speed. Performance on each subtest is converted to an age adjusted 
standardized score, from which VIQ and PIQ scores can be generated. The subtests 
were administered to all subjects according to standardised procedures specified in the 
WASI manual. Only raw scores for individual subsets were obtained. 
 
2.5.2.9 Beck’s Depression Inventory (BDI) 
 
The BDI (BDI-II) is a 21 question multiple choice self-report inventory for measuring 
the severity of depression. The most current version of the questionnaire is composed 
of items relating to depression symptoms such as hopelessness and irritability, 
cognitions such as guilt or feelings of being punished, as well as physical symptoms 
such as fatigue, weight loss and lack of libido. When the test is scored, a value of 0 to 3 
is assigned for each answer and then the total score is compared to a key to determine 
the depression's severity. Scores ≥17 indicate severe depression that needs to be treated. 
As depression is a common feature in patients with PCOS with incidence of up to 40% 
in some research studies [171, 223]  this test was administered so that any contribution 
of depression to cognitive performance could be controlled for.  
 
2.6  MRI data acquisition 
2.6.1 Materials 
MRI was done by Dr John Evans and Mr Peter Hobden, neuroscientists based at CUBRIC. 
MRI Scanner: General Electric HDx 3.0 T system. 
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a) Gradients: Twin-speed gradient system with gradient strength = 40 mT/m and 
maximum slew rate = 150 T/m/s. 
b) Radio Frequency (RF) Coils: Whole-body birdcage coil used for RF transmit; 
eight-channel head coil (made by MRI Devices Corp.) used for RF receive. 
c) Scanner Software Capability: Software to provide diffusion tensor imaging 
capability. 
d) Peripherals: Adequate padding for the head (wedge cushions, etc.); hearing 
protection (ear plugs); a peripheral pulse-oximeter; a squeeze-bulb (for the 
participant to communicate to the operator) 
2.6.2 Methods 
The participant is warned that the diffusion tensor imaging part of the protocol is 
‘louder than the other scans’ and that they ‘can expect the bed to vibrate quite a lot’. 
The participant is warned that ‘there will be irregularly timed knocking noises – and 
these will appear to move about as the scan progresses. 
1. Scanning: The integrated laser alignment system is used to landmark on the nasion, 
and the participant slid into the magnet, taking particular care not to trap the squeeze-
bulb/pulse-oximeter leads during the process. As an optional extra, the participant is 
provided with the option of watching a subtitled movie of their choice in the scanner 
via a rear projection onto a periscope mounted on the head coil. 
The sequence is a twice-refocused spin-echo EPI sequence [224] with a parallel 
imaging (ASSET) factor of 2. Sixty axially oriented slices are prescribed to cover the 
entire head. The field of view is 230 mm, with an acquisition matrix of 96 × 96 and a 
slice thickness of 2.4 mm. A total of 66 images were acquired at each of 60 slice 
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locations. Six images are acquired with no diffusion- weighting gradients applied, and 
60 diffusion-weighted images are acquired at a b-value of 1,200 s/mm2 .The diffusion-
weighted images were acquired with encoding gradients applied along 60 non-collinear  
directions. The echo time is 87 milliseconds, and the sequence is triggered to the 
cardiac cycle via a pulse-oximeter placed on the participant’s forefinger.  Each image is 
initially stored in DICOM format. We then convert the separate DICOM images into a 
4D data set (with ‘time’ or ‘diffusion-weighted measurement’ as the fourth dimension) 
in the NIFTI imaging   format. 
Fluid attenuated inversion recovery scans (FLAIR) were also obtained. The            
FLAIR  pulse sequence is an inversion recovery technique that nulls fluids and is 
commonly used in brain scans to suppress cerebrospinal fluid (CSF) effects on the 
image so as to detect subtle changes at the periphery of the hemispheres and in the 
periventricular region close to CSF[225]. Acquisition time was 19 minutes. The 
acquired images were corrected for distortions introduced by the diffusion-weighting 
gradients and for between-slice motion with appropriate reorienting of the encoding 
vectors [226] before a model was fitted to the data to estimate the diffusion orientation 
in each voxel. Images were visually inspected for the presence of white matter 
hyperintensities. On this basis, two subjects were excluded from further analysis. 
Once the 4 D (Diffusion weighted image) is obtained it is important to correct it for 
subject motion and eddy current induced distortions. Although the twice-refocussed 
spin-echo sequence will ameliorate much of the eddy currents, residual distortions are 
corrected by using a global affine registration software package which was done using 
the Explore-DTI software package [227]. Further distortions that commonly occur are 
partial volume effects (PVE) which can confound the results of diffusion MRI studies 
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because of tissue loss or atrophy. This depends on the degree of brain atrophy which 
affects the amount of CSF partial voluming as decreasing volume of white matter 
structures has been shown to increase the relative contribution of PVE contaminated 
voxels due to an increase in surface  area to volume ratio. This occurs in areas where 
white matter abuts the CSF spaces. This problem was addressed by Free water 
elimination method [228, 229] .This was done by modelling the effect of cerebrospinal 
fluid contamination on intra-voxel diffusion data directly by adopting a two 
compartment model and fitting two tensors to diffusion data, one anisotropic and one 
isotropic with diffusion characteristics of free water. The advantages of this technique 
is that it can be employed in data acquired by single b-value acquisition protocols. A 
by-product of this method is that it provides a voxel-wise map of tissue volume  
fraction(f), which might provide complementary information on tract structure 
attributable to atrophy at a microstructural scale [230]. 
The final stage in a standard Diffusion Tensor MRI pipeline is to derive parameters of 
interest from the diffusion tensor. Maps of the following microstructural measures were 
then created: Mean diffusivity, Axial Diffusivity and Fractional anisotropy and the 
principal diffusion orientation which can be used to create directionally encoded colour 
maps[185] or for fibre tracking analyses [195, 196, 231]. 
2.6.3 White matter Tractography and Tract specific measures 
White matter tractography was carried out by on the assumption that previous positive  
studies in obesity, ageing ,insulin resistance and diabetes have shown changes in white 
matter microstructure and similar changes might be reflected in our cohort of patients 
with PCOS. Based on previous studies 3 major white matter tracts connecting frontal, 
temporal and parietal regions namely the Fornix, Uncinate Fasciculus and the 
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Parahippocampal Cingulum were selected [202, 232-234]. I did the white matter 
tractography initially under the guidance of Dr Claudia Mettzler-Baddeley and Dr 
Michael O’Sullivan who trained me through the process of obtaining accurate and 
reproducible white matter tractography using the EXPLORE-DTI software and 
supervised me through the first six MRI images. I was blinded to the dataset containing 
the MRI images before I started the tractography. 
    
Fig 2.3 A schematic diagram of 2 types of Region of Interest (ROI) operations. When the first ROI 
(seedpoint) is drawn, all tracts that penetrate the ROI are retrieved (A). If the second ROI is applied as an 
“AND” operation, the fibres that penetrate both ROIs are retained (B). If a “NOT” operation is used, a 
subset of the fibres penetrating the NOT ROI is removed (C).  
 
Fibre tracking was performed using a multi-ROI approach. This was used to reconstruct 
tracts of interest which exploits existing anatomical knowledge of tract trajectories. 
Tracking was performed from all pixels inside the brain and results penetrating the 
manually defined ROIs were assigned to the specific tracts associated with the ROIs. 
When multiple ROIs were used for a tract of interest, two types of operations were 
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employed namely ‘AND’ and ‘NOT’, the use of which would depend on the 
characteristic trajectory of each path.(Fig 2.3) 
Fornix: The fornix is an integral white matter bundle which projects into the medial 
diencepahalon and is part of the limbic system. It has been demonstrated as the link 
between the hippocampus, mammilary bodies, and the anterior thalamic nuclei [235, 
236]. Recent Diffusion weighted imaging studies have found that changes in fornix 
microstructure in young people correlate selectively with recollective memory [237]. 
These studies closely support clinical studies of fornix pathology [238, 239] although 
the specificity of this association remains unclear.  
Uncinate Fasciculus (UF): is a bidirectional pathway that links the anterior temporal 
lobe with the orbital and medial prefrontal cortex. It provides an afferent sensory route 
for prefrontal cognitive functions and is known to be associated with auditory-verbal 
memory and declarative memory [240, 241]. Variations in UF microstructure have been 
linked to aspects of memory in older adults [241]. 
Parahippocampal cingulum : include white matter fibres which link the hippocampal 
formation with the cingulate cortex and recent evidence suggests that it may be critical 
for strategic memory procceses related to successful encoding/retrieval and meta 
memory.[242] 
Tractography based on the diffusion tensor model has been shown to generate 
anatomically plausible and reproducible reconstructions of tracts within regions of 
coherently oriented fibres [196, 197]. Tractography was performed using Explore-DTI 
software package. The deterministic tracking algorithm estimated the principal 
diffusion orientation at each seed point and propagated in 0.5 mm steps along this 
direction. The fibre orientation(s) was/were then estimated at the new location and the 
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tracking moved a further 0.5 mm along the direction that subtended the smallest angle 
to the current trajectory. In this way, a pathway was traced through the data until either 
FA fell below an arbitrary threshold (in this case 0.15) or the direction of the pathway 
changed through an angle of 60°.  
Whole-brain tractography was performed using every voxel as a seed point. Three-
dimensional reconstructions of the three tracts (Fig. 2.4) were then extracted from 
whole-brain tractograms by applying multiple waypoint regions of interest (ROIs) 
masks. Representative ROIs for the three tracts are shown in Figure 4.3. All ROIs were 
manually drawn in native space on colour-coded fibre orientation maps for each 
individual dataset by myself using landmark techniques that have previously been 
shown to be highly reproducible. These are detailed for each tract below. The mean FA 
and MD were then calculated for all reconstructed pathways in Explore-DTI by 
averaging the values sampled at each 0.5 mm step along the pathways providing tract-
specific means of FA and MD for the left and the right UF, left and right PHC, and the 
fornix. The precise neuropathological correlates of FA and MD are not known but these 
measures were adopted as they are most widely used and FA has been shown to have 
neurophysiological relevance. 
Fornix - A seed point ROI (Fig. 2.4A, blue) was placed medially on a coronal slice 
around the fornix bundle at the level of the entry point of the anterior pillars into the 
body of the fornix, approximately below the sagittal midline of the corpus callosum. An 
AND ROI (Fig. 2.4A, green) was defined on an axial slice capturing the crus fornici in 
both hemispheres at the level of the inferior border of the splenium of the corpus 
callosum. NOT ROIs (Fig. 2.4A, red) were drawn on coronal slices rostral to the 
anterior fornix pillars and caudal to the crus fornici as well as on axial slices through 
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the corpus callosum and the upper pons to exclude streamlines from the corpus 
callosum and the corticospinal tract. After visual inspection, obvious anatomically 
implausible outlier streams, if present, were removed using additional NOT ROIs. 
Uncinate fasciculus - A seed point ROI was drawn on a coronal slice around the region 
where the UF enters the frontal lobe immediately rostral to the genu of the corpus 
callosum (Fig. 2.4B). An AND ROI was placed on an axial slice capturing the UF 
bundle at the point where the bundle bends into the inferior temporal lobe region. This 
bend was visually identified on the midline sagittal plane with the axial slice being 
placed at a level immediately dorsal to the upper pons. A NOT ROI was drawn across 
the coronal slice level with the front of the pons to remove tracts of the internal frontal-
occipital fasciculus. The tract was then visually inspected and any obvious outlier 
streamlines that were not consistent with the known UF anatomy were removed using 
additional NOT ROIs. This procedure was performed for both hemispheres. 
Parahippocampal cingulum: A seed point ROI was placed on an axial slice level with 
the pons–midbrain junction around the cingulum fibre bundle that runs caudal and 
lateral to the pons (Fig 2.4C). A NOT ROI was drawn across the midline sagittal plane 
to remove inter-hemispheric projections. After visual inspection, further NOT ROIs 
were placed, when necessary, to remove projections to the occipital lobe and any outlier 
tracts that were not consistent with the known anatomy of the PHC. This procedure was 
performed separately for the left and the right PHC. 
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Fig 2.4 Tractography using region of interest (ROI waypoints) Reconstruction based on a 
standardized atlas of white matter tracts. 
  
Fornix (A) - A seed point ROI (blue) drawn medially on a coronal slice around the fornix bundle at the 
level of the entry point of the anterior pillars into the body of the fornix and an AND ROI (green) defined 
on an axial slice capturing the crus fornici in both hemispheres at the level of the inferior border of the 
splenium of the corpus callosum. 
 
Uncinate fasciculus (B) - A seed point ROI (blue) drawn on a coronal slice around the region where the 
UF enters the frontal lobe immediately rostral to the genu of the corpus callosum and an AND ROI 
(green) placed on an axial slice capturing the UF bundle at the point where the bundle bends into the 
inferior temporal lobe region. 
 
Parahippocampal cingulum (C) - A seed point ROI (blue) placed on an axial slice level with the pons–
midbrain junction around the cingulum fibre bundle that runs caudal and lateral to the pons. 
 
2.6.4 Tract –based spatial statistics (TBSS) 
This method is executed by the software FSL (FMRIB software Library). TBSS was 
performed by Dr Rok Berlot, a neuroscientist based at Kings College London. Data 
analysis and the results were provided by Dr Berlot. 
The summary of TBSS is presented as follows.  
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• Identify a common registration target and align all subjects’ FA images to this target 
place.  
• After identifying the most typical subject as the target, a mean FA skeleton image 
from all aligned images by applying ‘thinning’ (non-maximum-suppression 
perpendicular to the local tract structure). Threshold this to remove areas of low FA 
values and areas with high inter-subject variability.  
• Project each subjects’ FA data onto the skeleton by filling the skeleton with FA values 
from the nearest relevant track centre. This is done by searching along all voxels in the 
local ‘tract perpendicular direction’, and the voxel with the highest FA is identified as 
the centre of the tract. 
• Carry out voxel-wise statistics across subjects on the skeleton-space FA data.  
The detail of each step is described in the section below. 
Voxel-wise  statistical  analysis of diffusion data was carried out using TBSS  (Tract-
Based spatial Statistics), part of FSL (FMRIB Software Library 
http://www.fmrib.ox.ac.uk/fsl/ Version 5.0)[205]. The recommended FMRIB58_FA 
standard-space image was used as the registration target. Each subject’s aligned FA data 
were then projected to the mean FA skeleton. Voxel projections defined in this way 
were applied to project voxel values of MD, AD, RD and f to the white matter skeleton 
for each subject. Resulting data were used to generate voxel-wise statistical 
analyses. The details of this analysis was carried out as below. 
Preprocessing  
The first step in TBSS is preprocessing the FA image. It includes removing eddy 
current which is created by gradient coils of MRI and head motion during scanning. 
Head motion creates rigid body image motion while eddy current forms first order 
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linear image transformation .[243] Eddy current is removed by using built-in software 
eddy current correction in FSL. After preprocessing, diffusion tensors can be calculated 
with extraction of tensor eigenvalues measurement of FA. Finally, the BET brain 
extraction tool is used to exclude nondiffusion brain voxels from further 
consideration.[244]  
Non-linear alignment  
The next step for aligning multiple FA images to each other is using nonlinear 
alignment.(Fig 2.5) Here, the main anatomical features of the images will not change 
and keeping the general tract structure intact is important to prepare for the next stage 
(projection of data on tract skeleton). Non-linear registration was completed by 
registering FA images to FMRIB58_FA standard-space image, an averaged FA map 
included with the software package.[245] 
 
Fig 2.5 Tract Based Spatial Statistics Voxel-wise non-linear registration to prealign all subject’s FA 
images which is done by registering all subjects FA images to a  standard FMRIB58_FA standard space 
image (high-resolution averaged of 58 well-aligned good quality FA images from healthy male and 
female subjects aged between 20-50). 
 
Identifying the target for alignment 
Registration of a target is more successful if the target is a real FA image rather than an 
average FA image as a single subject will be sharper than an averaged image, giving 
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better information to drive the alignment. A single subject’s FA image is identified to 
act as the target for all nonlinear registrations. This is done by registering every subject 
to every other subject, summarising each warp field by its mean displacement, and 
choosing the ‘most representative’ individual. 
Creating mean FA image and skeleton:  
After identifying the most typical subject as the target, all subjects’ FA images are 
aligned to this. This target image is then aligned into MNI152 (Montreal Neurosciences 
Institute) standard space. MNI152 is a standard template derived by the averaging of 
152 diffusion tensor images of the brain obtained from 152 different people. An 
‘average’ brain is seen when visualising the MN152 image. Registration of all study 
subjects’ scan to this space enables easier statistical analysis of imaging data.  Every 
image is transformed into 1x1x1mm MNI152 space by combining the nonlinear 
transform to the target FA image with the affine transform from that target to MNI152 
space.  All subsequent processing is carried out using this space and resolution. Affine 
and nonlinear registrations were combined in order to avoid resampling the images 
twice. The mean FA image is created by averaging the transformed images. This image 
is smooth due to averaging of FA images across subjects and resolution up sampling. It 
is then used to create the skeleton image which represents all the ‘common’ tracts of the 
aligned images. 
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Fig 2.6. Tract based spatial statistics (TBSS) Mean fractional anisotropy (FA) image with no 
smoothing. Mean FA is fed into tract skeleton generation which aims to represent all tracts which are 
common to all subjects. This is highlighted in the figure above in white in the sagittal (left), coronal 
(middle) and axial (right) views. 
 
 
        A                    B 
Fig 2.7. Examples of fibre bundles; a thick sheet with a thin surface as its skeleton (A) and a ‘tube’, 
with a line as its skeleton (B). Tract skeleton will represent each white matter tract as a single line or 
surface running down the centre of the tract. Contiguous sets of tracts appear as curved sheets as shown 
in figure A (eg the corpus callosum) or, less frequently, curved ‘‘tubes’’ (e.g., the cingulum bundle) as 
shown in figure B. 
 
The next step involves making the skeleton image from the mean FA image. The first 
step is to estimate local surface perpendicular direction (at all voxels in the image) and  
search for all voxels in this direction (tract perpendicular direction), the one with the 
highest FA value is identified as the centre of the tract. If the voxel of interest is far 
from tract centre, the FA value will be higher in the neighbouring voxels on one side of 
the voxel than on the other side and the direction in which it is highest shows toward 
the centre of the tracts. This can be explained in Figure 2.8 below. 
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Fig 2.8. A. Original mean FA image with final skeleton and region of interest (ROI) used for sub-image. 
B. Skeletonisation, using local FA centre-of-gravity to find tract perpendiculars (search for the voxel 
with highest FA which is projected on to the skeleton. This results in a FA skeleton which is thresholded 
in order to remove areas with large inter subject variations . 
 
The constructed skeleton FA value is thresholded in order to remove areas with large 
inter subject variations. 
                                        
            A             B 
 
Fig 2.9. A) Example of white matter skeleton which is shown in green. This defines the set of   voxels  
used in all subsequent processing. All FA image (containing all subjects' aligned FA data) and, for each 
"timepoint" (i.e., subject ID), is projected onto the mean FA skeleton. This results in a 4D image file 
containing the (projected) skeletonised FA data. 
 
Fig 2.9 B) Voxel-wise statistics on skeletonised FA data (Comparision of data across groups) 
The final step involves projection of data using voxel-wise statistical analysis (measures of diffusion 
such as axial diffusivity (AD), mean diffusivity (MD), radial diffusivity (RD), f (tissue volume fraction) 
onto the skeleton which delineates for eg which FA skeleton voxels are significantly different between 
two groups of subjects 
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Projecting individual subjects FA onto skeleton 
After the skeleton tract is ready, we now ‘project’ each subject FA image onto the mean 
FA skeleton. This projection from the tract centre to the mean skeleton is accurate  
providing a sort of “fix” for such misalignments in actual tracts. For each voxel in the 
skeleton tract, a maximum FA value in a perpendicular direction is searched from a 
subject’s FA image. The perpendicular directions of the skeleton are already prepared 
from the previous skeleton formation. This assignment is valid only in perpendicular 
direction as the change in FA value is greatly pronounced in this direction than the 
parallel direction. There are two limitations for the searching of maximum FA value to 
the skeleton tract. The first limitation is that search is limited to voxels closer to the 
starting section of the skeleton than that of the farther section of the skeleton. Space 
between two separate sections of skeleton are divided into two and each skeleton 
section can search voxels from its space. This is achieved by using distance map which 
shows the distance of each voxel from the nearest skeleton voxel. This constraint also 
ensures each voxel in the image is mapped only to a single point in the skeleton.  
Statistics and thresholding 
At this stage the data are ready to be fed into voxel-wise cross subject statistical 
analysis. Since each FA image of the subjects is aligned into a common space using 
constrained nonlinear registration, common tract skeleton has been formed, and each 
subject FA has been projected into the skeleton via perpendicular search for local tract 
centre. In order to find group differences between two groups, an unpaired t-test is 
used.  
 
 
65 
 
2.7 Statistical Analysis 
In  the  absence  of a priori  information  about  the  most  sensitive  cognitive  tests  in 
PCOS, I chose to generate a composite score from Principal Components Analysis 
(Appendix 1 Page 95). The principal component was derived from a combination of the 
following tests: Digit Span, Free and Cued Selective reminding test, Rey Osterrieth 
Complex figure test, Verbal Trails, Digit Symbol Substitution and the letter and 
semantic fluency test. General cognition score which accounted for 35% of the variance 
across all test scores, was used as a summary score and compared across the two groups 
using an unpaired t-test. A threshold of significance of 0.05 was used for this single 
comparison. Subsequent comparisons for individual test scores were performed as a 
means of exploring the pattern of any significant difference between groups: 
uncorrected p-values are presented but not interpreted in terms of significance for 
individual test scores. 
For TBSS, two-sample unpaired t-tests for reduced and increased DTI measures in 
PCOS patients compared to controls were performed. Additionally, microstructural 
measures were correlated with the value of the general cognition score and hormonal 
levels in each group separately. Statistical inference was based on permutation: five 
thousand permutations were performed using randomise software [246]. Resulting  
statistical  maps  were  thresholded for p <0.05, correcting  for  multiple comparisons 
using threshold-free cluster enhancement (TFCE) [247].  
 
2.8 Power Calculations 
In the absence of any prior data in subjects with PCOS, sample size calculations were 
based on data from a previous study which examined the influence of BMI on corpus 
66 
 
callosum microstructure [207]. A BMI difference of 10kg/m2 corresponded to a 
difference in FA of 0.05 (SD of FA measures 0.04). I  calculated that a  sample of 18 
participants per group would provide at least  95%  power  to  detect  a  between-group  
difference  in FA of 0.05 at the 5% significance level. 
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CHAPTER 3  RESULTS   
3.1 Introduction 
There is increasing appreciation of the importance of mid life risk states and it’s 
association with late life cognitive decline. Risk states in middle age include 
behavioural factors such as smoking [44, 248], aspects of cardiovascular function such 
as hypertension [33, 249-251], cardiac structure and metabolic traits. Metabolic factors 
shown to confer risk in cohort studies include diabetes [202, 252-254] and prediabetes 
[255, 256]. Adiposity generally indexed by body mass index (BMI), has also been 
associated with subsequent dementia [19, 29, 257]. A negative association between 
visceral adiposity and performance in the domain of verbal learning and memory has 
been observed in recent studies in healthy young women aged between 20 – 45 years of 
age [29] . Insulin resistance is the main pathological condition underlying vascular 
disorders, such as diabetes, obesity and cardiovascular disease and has been implicated 
as a major risk factor for cognitive decline in recent studies [258-260] . We 
hypothesised that women with PCOS and hyperandrogenism along with insulin 
resistance would demonstrate worsening cognitive function in the context of working 
and episodic memory compared to healthy volunteers.  
3.2  Aims 
The aims of this Chapter are to: 
1. Compare the demographic, anthropometric and metabolic characteristics between 
PCOS subjects and healthy volunteers. 
2. Compare cognitive function between subjects with PCOS and healthy volunteers. 
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3.2.1 Study recruitment 
 
From the departmental database and outpatient endocrine clinics at the University 
Hospital of Wales, 18 women with a diagnosis of PCOS were identified. From local 
advertisement, 22 women expressed an interest in being a healthy volunteer. Healthy 
volunteers (n=18, all Caucasian) were recruited as controls with 1 to 1 matching for age 
and BMI. For each individual patient, a control was identified matched for age (within 
2 years) and BMI (within 2 kg/m2). Controls needed to have regular menstrual cycles 
(menses every 27–32 d). Control subjects with signs of hirsutism or with a personal 
history of diabetes or hypertension, or a family history of PCOS were excluded. 
 
3.2.2 Demographic Data  
 
The number of subjects in each group, their age, BMI, smoking status, ethnicity and 
medications taken are presented below. 
Eighteen women with PCOS (n = 18, 16 Caucasian and 2 Afro – Caribbean) and 
eighteen healthy volunteers (n = 18) participated in the study. The mean age and 
standard deviation of the PCOS and HV groups were 31 ± 6 years and 31 ± 7 years 
respectively, which was evenly matched (p=0.9). Results are displayed in Table 3.2. 
There were two current smokers in each group. Two subjects in each group were taking 
a combined oral contraceptive pill. No subjects were on antidepressants. 
Participants in the PCOS group included all subphenotypes as described by the 
Rotterdam criteria and are shown below in Table 3.1.  
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Table 3.1  PCOS (subphenotypes as per Rotterdam Criteria) 
PCOS (subphenotype) No (%) 
PCO Complete  8  (44)` 
Normo-androgenic  5  (28) 
Non Polycystic Ovary   1  (6) 
Ovulatory  4  (22) 
 
PCO complete : Presence of oligo/anovulation (O) + polycystic ovaries (P) + hyperandrogenism (H)  
Normo-androgenic : Presence of oligo/anovulation (O) + polycystic ovaries (P) 
Non Polycystic ovary : Presence of oligo/anovulation (O) + hyperandrogenism (H) 
Ovulatory : hyperandrogensim (H) + Polycystic ovary (P) 
 
Table 3.2 General characteristics of the study population 
 
 
 PCOS (n=18) 
Mean ± SD 
 
 
 Controls (n=18) 
Mean ± SD 
 p-value 
 
 
 
 
 
 
Age 
  
31 ±6 
 
 
  
31 ±7 
  
0.9 
Estimated 
Premorbid 
Intelligence 
 
 
 
122 ± 4 
  
 
 
 121 ± 8   0.35    
 
Weight (kg) 
  
78 ±21 
   
76 ±15 
  
0.68 
  
 
BMI (kg/m²) 
  
30 ±6 
   
29 ±6 
  
0.61 
  
 
Systolic BP 
(mmHg) 
  
119±8 
   
120±11 
  
0.96 
  
 
Diastolic BP 
(mmHg) 
 
 
 
66 ±8 
   
69±10 
  
0.36 
  
 
Waist (cm) 
  
91 ±15 
   
86 ±13 
  
0.31 
  
 
Hip (cm) 
  
111 ±16 
   
106 ±12 
  
0.24 
  
 
Visceral fat area 
(cm²) 
 
 
 
31 ±23 
   
26 ±14 
  
0.46 
  
 
Subcutaneous fat 
area (cm²) 
 
 
 
287 ±119 
   
298 ±114 
  
0.78 
  
 
Total fat area (cm²) 
  
318 ±133 
   
324 ±124 
  
0.89 
  
 
BMI: body mass index; Estimation of premorbid intelligence was based on the National Adult Reading 
-Revised. 
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3.3 Biochemical Characteristics of the Study Population 
 
There was a significant increase in the testosterone, androstenedione and Insulin AUC 
in subjects with PCOS compared to controls. Biochemical parameters are shown in 
Table 3.3. 
3.3.1 Glucose Tolerance Status 
 
5 subjects in the PCOS group and 2 controls  had  prediabetes  as  per  the  World 
Health Organisation (WHO) criteria which is described in Table 3.4. 
Table 3.3 Biochemical characteristics of the study population 
    PCOS (n=18) 
    Mean ± SD 
      HV(n=18) 
      Mean ± SD 
 
       p-value 
 
Testosterone 
(nmol/l) 
 
 
 
 
1.6±0.6 
  
0.9 ±0.6 
  
0.01 
Androstenedione 
(nmol/l) 
 
 
 
13.4 ± 7.3  6.8± 2.5  0.001 
hsCRP (mg/l) 
 
 1.2 (0.2 -21.8)  0.9 (0.1 -16.7)  0.73 
Total cholesterol 
(mmol/l) 
 
 
 
4.6 ±1.3  4.8 ±1.1  0.67 
Triglycerides 
(mmol/l) 
 
 
1.2 ±1.4  1.0 ±0.5  0.52 
LDL cholesterol 
(mmol/l) 
 
 
 
2.4 ±1.4  2.5 ±1.3  0.79 
HDL cholesterol 
(mmol/l) 
 
Insulin AUC (pmol 
min/litre) 
 
HOMA-IR 
 
Glucose AUC (mmol 
min/l 
 
 
     
1.2 ±0.5 
 
 
93151 ± 42694 
 
 
2.6164  ± 0.95 
 
764 ± 217 
 1.3 ±0.6 
 
 
61933 ± 29614 
 
 
2.005  ± 1.43 
 
692 ± 133 
 0.65 
 
 
0.04 
 
0.32 
0.24 
 
hsCRP: high sensitivity c-reactive protein; LDL: low density lipoprotein; HDL: high density lipoprotein; Insulin 
AUC:Insulin area under curve (during oral glucose tolerance test); HOMA-IR: Homeostatic model assessment 
for insulin resistance.  Serum Testosterone , Androstenedione and Insulin  area under curve (Insulin AUC)  are 
significantly  raised in the PCOS group compared to controls
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Table 3.4 Outcome of screening tests for diabetes and dysglycaemia in PCOS and healthy volunteers 
Subject No 
 
Status 
 
Diagnosis HbA1c 
mmol/mol 
FPG 
mmol/l 
2 hour glucose 
mmol/mol 
BMI  
kg/m2 
Age 
years 
1 PCOS IGT 40 4.6 8.0 32.5 37 
2 PCOS IGT 30 4.9 8.4 29 31 
3 PCOS IGT 43 4.3 9.1 36.5 33 
4 PCOS IGT 37 5.8 8.3 44 24 
5 PCOS IGT 33 4.7 7.8 30.1 33 
6 HV IGT 36 5.2 8.4 33 36 
7 HV IGT 38 5.4 8.6 32 34 
 
PCOS: Polycystic Ovary Syndrome; HV:Healthy Volunteer; FPG: fasting plasma glucose; BMI: body mass index; IGT: impaired glucose tolerance 
 
 
Diabetes: WHO/ADA HbA1c ≥ 48 mmol/mol or FPG ≥7.0mmol/l or 2 hour glucose OGTT ≥11.1mmol/l 
Impaired glucose tolerance: WHO/ADA FPG <7.0mmol/l and 2 hour glucose OGTT ≥ 7.8mmol/l 
Impaired fasting glycaemia: WHO FPG ≥ 6.1 mmol/l and <7.0 mmol/l, ADA FPG ≥5.6 mmol/l and < 7.0 mmol/l 
High risk of diabetes: WHO HbA1c 42-47mmol/mol, ADA 39mmol/mol-47mmol/mol 
Results displayed in red are abnormal as per WHO criteria 
Results displayed in blue are abnormal according to ADA criteria; this is also the cut off for an oral glucose tolerance test according to NICE 
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3.4  Cognitive Function Tests 
 
There are very few studies which have looked at the effects of PCOS on cognitive 
function and have focussed predominantly on the effects of androgens and estrogen. 
Futhermore these studies have been limited by the lack of adequately matched controls 
[177] or sample size [208]. Cognitive function was assessed in our study cohort as 
previously explained where they performed a battery of neuropsychological tests and 
the results were compared across the PCOS group and controls.  
3.4.1 Results 
No individual in either group had evidence of depression based on Beck depression 
inventory score (scores all < 15). The groups were well matched for premorbid 
intelligence as assessed by the National Adult Reading Test. Both groups showed 
similar high levels of general intelligence with scores of 122.4 in the PCOS group and 
120.5 in controls (p=0.35).  
Cognitive performance was degraded in patients with PCOS compared to controls. For 
the summary score, the between group difference was significant: t = 2.88, P =.007. 
(Appendix 2 Page 97) Subjects with PCOS performed less well compared to controls in 
tests of short term and verbal working memory as measured by the Digit Span Task. 
Current IQ was lower in the PCOS cohort as well which was evaluated using the 
Wechsler Abbreviated Scale of Intelligence (WASI) although it must be emphasised 
that only raw scores were calculated for this measure of intelligence. Controls showed a 
better level of functioning across the domains of episodic memory, attention and 
executive function. Table 3.5 summarises performance on underlying individual 
cognitive measures. 
Metabolic status and cognition in PCOS  
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No correlation was observed between cognitive performance and testosterone or Insulin 
AUC in subjects with PCOS (testosterone : r = -0.12, P = 0.64; insulin AUC : r = 0.01, 
P = 0.98). 
Table 3.5 Performance on individual cognitive tests 
 
Cognitive Function Tests 
 
Population(n=36, 
mean ± SD) 
   
PCOS(n=18, 
mean±SD) 
 
 
 
 
 
 
Controls(n=18 
mean±SD) 
 
 
 
 
p-value 
         
Intelligence and Executive 
Function 
       
National Adult Reading Test 121.4 ± 6.1  122.4 ± 3.6  120.5 ± 7.9  0.35 
Digit span forward 12.8 ± 2.2  12 ± 1.9  13.6 ± 2.2  0.02 
Digit span backward 8.2 ± 2.5   7.4 ± 2.5  9.1 ± 2.3  0.04 
Digit Symbol 86.5 ± 14.5   83 ± 15.8  90.1 ± 12.5  0.14 
Verbal Trails (switching cost) 39.5 ± 17.4   44.5 ± 21.2  33.4 ± 9.8  0.03 
Verbal Trails (errors) 0.8 ± 1.3   1.1 ± 1.5  .55 ± 1.1  0.23 
Letter Fluency 38.6 ± 10.8  38.1 ± 11  39.1 ± 11  0.79 
Category Fluency 41.8 ± 7.2  39.6 ± 7.5  44 ± 6.3  0.06 
Stroop Colour Word Test 
(duration) 
112.3 ± 22.2  118.3 ± 22.7  106.4 ± 20.5  0.11 
WASI (vocabulary) 66.9 ± 8   64 ± 9.2  69.88 ± 5.5  0.02 
WASI (block design) 52.6 ± 12   49.1 ± 13.7  56.2 ± 8.9  0.07 
WASI (similarities) 41.5 ± 4.4   39.5 ± 4.8  43.61 ± 2.8  0.04 
WASI (matrix reasoning) 27.5 ± 5.1  27.1 ± 6.6  27.8 ± 3.2  0.7 
Episodic memory          
FCSRT Immediate recall 14.6 ± 2.3  13.7 ± 1.9  15.4 ± 2.4  0.03 
FCSRT Free  recall 38.4 ± 8.8  35.7 ± 8.9  41.1 ± 8.1  0.06 
FCSRT Total recall 43.2 ± 7  41.7 ± 7.7  44.7 ± 6.1  0.20 
FCSRT Delayed free recall 14 ± 2  13.2 ± 2.4  14.9 ± 1.2  0.01 
FCSRT Delayed total recall 15.9 ± 0.3  15.8 ± 0.4  15.9 ± 0.2  0.65 
Rey-Osterrieth Complex 
figure  
28.6 ± 5.9   26.7 ± 6.9  30.6 ± 4  0.05 
NART: National Adult Reading test, a score of premorbid intelligence, General Population mean ± S.D: 
107.4 ± 17.1 [261] higher score indicates better performance 
Verbal Trails (switching cost and errors)/ Stroop Test: higher readings indicate poor performance   
Digit span forward / Digit span backward: no normative data: higher score indicates better performance 
Digit Symbol Test:Population mean ± S.D: 80.26 ± 14.76 [262]: higher score indicates better performance 
Letter Fluency  mean ± S.D: 43.1 ± 12.2 : higher score indicates better performance.  
WASI: Wechsler Abbreviated Scale Of Intelligence, all scores indicated are raw scores for vocabulary, block 
design,similarities and matrix reasoning, no normative data for raw scores recorded. 
 Rey-Osterrieth Complex Figure Test: Immediate Recall General Population mean ± S.D: 20.75 ± 5.75:       
 higher score indicates better performance [263] 
        FCSRT: Free and Cued Selective Reminding test: higher score indicates better performance. No normative   
        data available in the 18-45 year age group for the english version of this test [264]. 
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           3.5  Discussion 
 
The subphenotypes identified under the PCOS group showed a predominance of the 
PCO complete group who comprised 44% of the PCOS cohort. The two groups were 
well matched with reference to age and body mass index. No significant differences in 
anthropometric indices were observed between the 2 groups.  
The prevalence of newly established impaired glucose tolerance was higher in the 
PCOS group (27%) compared to the healthy volunteers (11%). This is not surprising as 
women with PCOS are at increased risk of developing glucose intolerance and diabetes 
[127, 265]. The prevalence rates of diabetes and impaired glucose tolerance in PCOS 
are between 2 to 10% [116, 141, 266] and 10 to 35% respectively [42-44]. In this study 
5(27%) subjects in the PCOS group had  IGT.  
Subjects with PCOS showed a significantly higher levels of testosterone and 
androstenedione compared to controls. This was anticipated since hyperandrogenism is 
common in women with PCOS, although the presence of biochemical 
hyperandrogenism is not absolutely necessary to establish a diagnosis of PCOS 
according to the Rotterdam criteria. 
Markers of insulin resistance (Insulin AUC) were significantly higher in the PCOS 
group. This is consistent with other studies. Previous authors have also shown increased 
basal and glucose- stimulated insulin levels in women with PCOS compared to weight-
matched controls [65],  and IR is present in PCOS independently of obesity [148] . 
However although the HOMA-IR was raised in the PCOS group this did not reach 
statistical significance. This is a major limitation of HOMA as many young PCOS 
women display stimulated but not fasting metabolic abnormalities [267]. In fact, 
HOMA in young PCOS patients may miss as much as 50% of IR as compared to 
OGTT with insulin-AUC calculations[268]. Hence measuring insulin AUC may be a 
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better measure than other tests to assess insulin resistance in non-obese PCOS patients 
[267]. 
Subjects  with PCOS  showed  subtle  decrements  across a broad range of cognitive 
tests as shown by principal component analysis despite similar education and 
premorbid intelligence. This was  an interesting finding as this could  not be attributed 
to BMI and age. However looking at the individual test scores there does not appear to 
be a  clear selective pattern of impairment, it is more a general degradation across 
several domains.  The Beck depression inventory was also applied which did not find 
any evidence of depression with all scores less than 15. This contrasts with studies in 
PCOS which showed an increased prevalence of depression [168, 169, 171]. This may 
be related to the small cohort of patients used in this study who did not show any signs 
of depression the presence of  which may have impacted on cognitive function test 
scores as seen in previous studies [269, 270]. Subjects in  both groups had a similar 
level of general intelligence. Barnard et al carried out an internet based computerised 
study which compared neuropsychological functioning in women with PCOS. They 
hypothesised that women with PCOS would display enhanced cognitive performance 
on sexually dimorphic tasks. However no difference in performance was observed  on  
mental  rotation  and spatial location tasks. Despite  presumed  hyper-oestrogenism  
women  with  PCOS  demonstrated  impaired  performance in terms of speed and 
accuracy on reaction time and word recognition tasks. The subjects in this study were 
stratified according to the use of anti-androgen medication and level of depression. This 
study did not evaluate the biochemical and anthropometric data of the subjects involved 
and failed to account for the cognitive impairments on the basis of raised testosterone 
levels [177]. Furthermore another study by Schattmann et al. [208] tried to study the 
possible influence of testosterone on cognitive function in women with PCOS. This 
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study compared 29 women with PCOS with raised testosterone levels with 22 age and 
education matched women with normal testosterone levels. Women with PCOS 
exhibited significantly worse performance on tests of verbal fluency, verbal memory, 
manual dexterity and visuo-spatial working memory. Another study by the same group 
investigated cognitive functioning (visuospatial abilities, verbal abilities, and perceptual 
speed) in women with PCOS after manipulation of testosterone. Hormonal treatment to 
suppress the level of free Testosterone with cyproterone acetate plus oestrogen did not 
result in changes in most of the cognitive functions, except for verbal fluency, which 
appeared to improve. It must be remembered that the earlier studies were limited by 
poor case-control matching A recent study by Barry et al. found evidence of better 
visuo-spatial task performance in women with PCOS compared with subfertile controls, 
but this difference was no longer significant when age and BMI were controlled for in 
the analysis [271]. Another study evaluating effects of PCOS on cognitive function 
showed poor performance in the PCOS group on tests of spatial ability and manual 
dexterity with both reproductive and metabolic features such as menstrual cyle length, 
number of follicles , triglycerides, Free Androgen Index (FAI), androstenedione and 
HbA1c emerging as independent predictors [272]. There was no information on 
anthropometric or biochemical indices provided in this study. 
A study by Soleman et al. evaluated working memory in women with PCOS with the 
help of functional MRI [179]. This was a case control study with working memory 
being evaluated before and after treatment of subjects with PCOS with anti-androgen 
therapy. The incidence of anxiety and depression was found to be significantly higher 
in the PCOS group before hormonal manipulation but no differences were seen after 
treatament.  General level of premorbid intelligence as measured by the NART test 
showed no differences between the 2 groups which was similar to the findings in my 
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study. The groups were evenly matched for age and BMI. Differences in biochemical 
parameters were observed in the 2 groups with significant differences between the 2  
goups relating to testosterone, oestradiol ,LH levels and Free Androgen Index (FAI). 
Measures of insulin resistance were not evaluated as in our study which was 
significantly raised in the PCOS group. There was no difference found in reaction time 
in executing a working memory task before and after treatment with anti-androgens 
although women with PCOS made fewer errors while completing the task after 
hormonal manipulation. This may suggest that women with PCOS may need  
recruitment of additional neural resources during a working memory task suggesting 
less efficient executive functioning. 
The advantages of this study was that the subjects in each group were closely matched 
for age and BMI which are major confounding factors. Subtle decrements in cognitive 
function were observed in the PCOS group but I did not find any correlation between 
cognitive performance and testosterone or insulin AUC in PCOS. Although there is 
some evidence to suggest that manipulation of  testosterone  may improve cognitive 
outcomes these are far from conclusive.  I did not look into the effects of specific 
subphenotypes of PCOS and the effects on cognition. There are indications that 
menstrual pattern dependent oestradiol levels relate to working memory although this 
was not investigated in our study cohort [273, 274]. 
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CHAPTER 4 . WHITE MATTER TRACTOGRAPHY AND TRACT BASED  
 SPATIAL STATISTICS 
 
4.1 Introduction 
 
Some early evidence suggests that metabolic risk states may have an influence on brain  
structure . Diffusion tensor MRI is a non invasive technique that is  sensitive to  subtle  
alterations in white  matter  pathology  in the brain. It provides an unprecedented  
insight into the organisation of white fibres and tracts. Furthermore it provides 
quantitative indices of white matter fibres and tracts. Damage to white matter matter 
fibres such as demyelination and axonal changes may lead to changes in the diffusion 
of water molecules and therefore to a change in DTI parameters. Both Type 1 and Type 
2 Diabetes are associated with altered microstructural measures derived from  diffusion 
tensor MRI[206, 215, 275]. Several studies have now shown associations between BMI 
and white matter microstructure [203, 207, 276]. Furthermore in Type 2 diabetes 
,alterations in tract microstructure have been found to correlate with cognitive function. 
As PCOS is characterised by metabolic risk factors such as obesity and insulin 
resistance I chose to investigate brain structure in women in early adulthood with a 
diagnosis of PCOS. 
 
4.2 Aims 
 
The aims of this chapter are to present 
 
1. The results of the diffusion parameters of reconstructed individual white matter 
tracts in the study group with a view to exploring any changes in white matter 
microstructure in the prespecified tracts of interest. 
2. An analysis of diffusion MRI images to look for changes in white matter 
microstructure with the application of TBSS to compare between PCOS and 
controls. 
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4.3 WHITE MATTER TRACTOGRAPHY 
Introduction 
 
Tractography based on diffusion MRI was performed using ExploreDTI [226] software 
package. 4 white matter tracts were reconstructed as they are known to link components 
of memory networks.These tracts link frontotemporal regions and have an important 
role in episodic memory. Diffusion parameters that were used to quantify 
microstructural white matter abnormalities: Fractional anisotropy (FA), Mean 
Diffusivity (MD) and Axial Diffusivity (AD) were obtained for each tract. 
1.Fornix (Fig 4.1) 
2.Right and Left Parahippocampal cingulum (Fig 4.2) 
3.Uncinate fasciculus (Fig 4.3) 
FORNIX 
 
Fig 4.1 Example of reconstruction of the Fornix registered on native space of one 
participant obtained using EXPLORE-DTI software 
 
 
Fig 4.2 Example of reconstruction of the Uncinate Fasciculus registered on native 
space of one participant using EXPLORE-DTI software 
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PARAHIPPOCAMPAL CINGULUM 
 
Fig 4.3 Example of reconstruction of the Parahippocampal cingulum registered  
on native space of one participant using EXPLORE-DTI software 
 
 
Table 4.1 Group differences in fractional anisotropy (FA), mean diffusivity (MD) 
and axial diffusivity (AD) 
 
    Controls  PCOS              p value 
------------------------------------------------------------------------------------------------------------------------------- 
Fornix       
FA    0.37 ± 0.03  0.36 ± 0.03  0.264 
MD    1.22 ± 0.03  1.25 ± 0.04  0.561 
AD    1.76 ± 0.10  1.78 ± 0.12  0.752 
 
Uncinate Fasciculus (UF) 
FA    0.43 ± 0.01  0.43 ± 0.02  0.795  
MD     0.83 ± 0.12  0.82 ± 0.17  0.773 
AD    1.26 ± 0.16  1.25 ± 0.10  0.509 
 
Parahippocampal Cingulum (PHC) 
FA Left   0.38 ± 0.04  0.38 ± 0.06  0.593 
MD Left   0.80 ± 0.12  0.78 ± 0.18  0.118 
AD Left   1.15 ± 0.13  1.14 ± 0.19  0.301 
FA Right   0.39 ± 0.05  0.40 ± 0.04  0.140  
MD Right   0.80 ± 0.06  0.78 ± 0.09  0.190 
AD Right   1.17 ± 0.11  1.15 ± 0.16  0.124 
 
______________________________________________________________________ 
FA : dimensionless; MD : 10-3mm2/s ; AD : 10-3mm2/s  
Comparative data showing no differences in measures of diffusion (FA, MD and AD) across PCOS and 
controls obtained through specific white matter tractography of Fornix, Uncinate Fasciculus and 
Parahippocampal Cingulum 
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The above tabulated data (Table 4.1) presents the measures of diffusion in the three 
white matter tracts in the PCOS group and healthy volunteers. No significant 
differences were observed between the two groups. 
 
4.4 Tract Based Spatial Statistics (TBSS) 
 
No changes were observed in specifically reconstructed white matter tracts in Diffusion 
weighted tractography. This is a limitation of white matter tractography as a presumed 
region of interest is studied based on previous data which looked at the involvement of 
silmilar tracts connecting frontotemporal regions in conditions such as obesity and 
diabetes. 
After attaining diffusion measurements in each voxel in the brain, the images were all 
mapped to a single template  in order to compare measurements across the PCOS and 
control groups. This allows measures to be compared voxel by voxel (also described as 
‘voxel-based analysis’) with the problem of comparisions across  many voxels being 
addressed one of a number of statistical approaches that are widely accepted in 
neuroimaging research. The advantage of this approach is that it is free of a priori bias 
about the likely location of structural alteration in the brain. In this study I applied 
Tract-based spatial statistics which is a widely accepted approach for statistical analysis 
of diffusion data .  
For TBSS, two-sampled unpaired t-tests for reduced and increased diffusion measures 
in PCOS patients compared to controls were performed. Additionally microstructural 
measures were correlated with the value of the first Principal Component and hormonal 
levels in each group separately.  
This section aims to present the results and highlight the group differences based on 
TBSS with respect to: 
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1. Differences in white matter microstructure between PCOS and controls. 
 
2. Correlation between insulin resistance measured by insulin area under the curve  
(insulin AUC) and white matter microstructure. 
3. Correlation between androgens (testosterone) and white matter microstructure. 
 
4. Correlation between metabolic status , white matter microstructure and cognition      
        in PCOS.  
 
4.4.1 Results 
 
4.4.1.1 Diffusion metrics and white matter microstructure 
Analysis of diffusion MRI images revealed differences in white matter microstructure 
between PCOS and control groups. Areas of decreased AD in PCOS were found 
throughout the mean white matter skeleton. This is illustrated in Figure 4.4 in blue. In 
addition, tissue volume fraction was increased in the anterior part of main body of the  
corpus callosum and parts of anterior white matter which is illustrated in red in Figure 
4.4 . No significant differences in voxel-wise values of FA, MD or RD were found 
between the PCOS group and controls. 
 
83 
 
 
 
Fig 4.4A.Tract Based Spatial Statistics using voxelwise statistical analyses comparing axial diffusivity 
(AD) and tissue volume fraction(f) across PCOS and control groups. Mean AD and f in PCOS group are 
depicted in blue and red respectively. 
Mean white matter skeleton voxels showing significantly lower value of AD (blue) throughout the white 
matter skeleton and higher value tissue volume fraction in the PCOS group (red) compared with healthy 
volunteers. Results are shown in different cross-sections in coronal (top), axial (middle) and sagittal view 
(bottom). Letters x, y and z represent the location of the cross-sections according to standard coordinates. 
Displayed results are corrected for family-wise error and thresholded for P < 0.05. The white matter skeleton is 
shown in green and is generated from projection of mean fractional anisotropy (FA) data obtained from all 
subjects. Individual voxel values of each participants’ AD, mean diffusivity (MD), radial diffusivity (RD) and f 
are projected to the white matter skeleton with resulting data used to generate voxelwise statistical analyses 
across the PCOS and control groups. No differences were noted in FA, MD or RD. 
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Figure 4.4 B  Group differences based on Tract based Spatial statistics in Axial diffusivity (AD) and tissue 
volume fraction( f) 
Mean values of AD (depicted on the left side in blue) and tissue volume fraction f (red) across parts of the 
skeleton showing a significant group difference for each participant. AD in PCOS is significantly decreased 
compared to controls whereas the converse picture is seen with f which is raised in PCOS compared to controls. 
 
4.4.1.2 Insulin resistance and white matter microstructure 
No significant differences were observed between the PCOS and control groups in 
voxel-wise correlations between insulin AUC and AD. However there was a significant 
group by insulin AUC interaction. This is shown in Figure 4.5 A. This suggests that the 
relationship between insulin resistance and white matter microstructure differed in 
PCOS and control groups. 
To explore this further, mean values of AD were extracted from this region and plotted 
against insulin AUC. This is illustrated in figure 4.5 B. Increasing insulin resistance 
was associated with reduction of AD in controls (Pearson’s r = -0.75) but with 
increasing AD in those with PCOS (Pearson’s r = 0.73), a reversal of the relationship 
found in controls. The reduction in AD found, on average, in patients with PCOS 
compared with controls was evident in those with relatively normal insulin 
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AUC<100000pmol/min/l) but AD was increased in a subset of PCOS subjects with 
marked insulin resistance. 
 
 
Figure 4.5  Contrasting associations between white matter microstructure and insulin resistance in 
PCOS and healthy volunteers.  
 
A, White matter skeleton voxels exhibiting a significant group by insulin AUC interaction are shown in 
red (P < .05 corrected for familywise error). Results are shown in different cross-sections in coronal 
(left), axial (middle) and sagittal view (right). 
 
B, Graphical description of Mean Axial Diffusivity (AD) values extracted from the region of significant 
interaction for each participant and plotted against insulin Area under Curve (Insulin AUC). Although 
AD was reduced in the PCOS group as a whole the direction of association is positive in PCOS and 
negative in controls. 
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4.4.1.3 Androgens and white matter microstructure 
Serum testosterone correlated positively with both AD and FA in the PCOS group 
(Figure 4.6). No association was observed in control participants. The direction of 
effect was consistent with that found between insulin AUC and diffusion metrics, ie, 
increasing values of AD were associated with both increases in testosterone and insulin 
AUC (Figure 4.6) in patients with PCOS. 
4.4.1.4 Metabolic status and white matter microstructure 
No correlation was observed between cognitive performance and testosterone or insulin 
AUC in PCOS (testosterone: r = 0.12, P = .64; insulin AUC: r = 0.01, P =.98). No 
significant correlations were observed between microstructural measures and cognition. 
Similarly, no significant associations with cognitive performance were found in the 
control group. 
 
Figure 4.6. Correlation of testosterone level with microstructural measures in PCOS.  
 
Top panel A) White matter skeleton voxels exhibiting a positive correlation with fractional anisotropy (FA) 
shown in red. 
Bottom panel B) White matter skeleton voxels exhibiting a positive correlation with axial diffusivity (AD) 
shown in red. Displayed results are corrected for family-wise error and thresholded for P < .05. Results are 
shown in different cross-sections in coronal (left), axial (middle) and sagittal view (right). This illustrates a 
similar pattern of interaction as with Insulin AUC with increasing values of AD being associated with increase 
in testosterone level. 
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4.5 Discussion  
This was the first study to look at the effects of PCOS on white matter microstructure. 
The current study did not demonstrate microstructural abnormalities in the major white 
matter tracts of interest in subjects with PCOS. These specific tracts were reconstructed 
with the hypothesis that changes in white matter microstructure may be observed in the 
PCOS group as it is a heterogeneous disorder which encompasses risk factors of obesity 
and insulin resistance which have been associated with white matter abnormalities 
associated with cognitive dysfunction. Although these tracts can be affected in 
disorders of metabolic dysfunction such as diabetes[202] and obesity[277], as seen in 
previous studies, these may have not been elicited as the study was carried out in a 
relatively young cohort of patients between the ages of 18 and 45 when these changes 
are not likely to be apparent. Moreover the Rotterdam criteria was used for diagnosis 
which may have picked up subtle cases of PCOS which would contrast with the more 
severe phenotypes that would be diagnosed by other criteria such as NIH [278]. As I 
did not find any changes in white matter microstructure in the pre-specified regions of 
interest I proceeded to apply TBSS which is free of a priori bias about the likely 
location of structural alteration in the brain and is a widely accepted approach for 
statistical analysis of diffusion data. 
Although there were no significant differences in voxel-wise values of FA, MD or RD 
between the groups, PCOS was associated with a reduction in axial diffusivity in a 
large portion of the white matter skeleton and tissue volume fraction was increased in 
the anterior corpus callosum.  Similar findings have been reported in studies on sexual 
dimorphism. Kumar et al.[279] attempted to describe age-related axonal and myelin 
changes in various sites in the brain and sex-related differences in those areas in healthy 
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adults using DTI measures such as axial and radial diffusivity. There was widespread 
reduction of axial and radial diffusivity in the bilateral amygdala, anterior and mid 
thalamus, hypothalamus and superior pons, right inferior cerebellar peduncle and  
putamen in males. Axial diffusivity was significantly decreased in the mid corpus 
callosum compared to females. Another study combined DTI and diffusion 
tractography with myelin -water fraction (MWF) imaging to investigate sex differences 
in microstructural measures in the corpus callosum [280]. This study illustrated 
increased myelin density in males for the rostral body and the posterior mid-body of the 
corpus callosum. No significant sex differences existed for axial or radial diffusivity. 
The changes in myelin density are possibly concordant with my findings of increased f 
in the anterior part of the corpus callosum reflecting atrophy at a microstructural scale 
even though these studies address structural characteristics that are not necessarily 
closely correlated. This might suggest that an influence of androgens on brain structure 
produces alterations in PCOS that parallel the characteristics of the male brain. 
A positive association was seen between serum testosterone levels and axial diffusivity 
and fractional anisotropy. This was contrary to the evidence that white matter axial 
diffusivity is reduced in PCOS. Raised testosterone levels and insulin resistance in the 
PCOS group were associated with increasing axial diffusivity and this was despite a 
mean reduction in the PCOS group as a whole. These findings may be explained by a 
reversal of the normal relationship between microstructure and metabolic status in 
patients with PCOS, reflected in a significant group by insulin AUC interaction.  These 
findings raise the possibility that the brain responds differently to the effect of 
androgens in PCOS and perhaps appear to correlate with the findings of another study 
by Soleman et al which used functional MRI to evaluate working memory function. 
Group differences in brain activity were seen in the superior, inferior parietal lobe and 
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the superior temporal lobe in PCOS versus controls with no difference in performance 
during a working memory task. Although hormonal levels were not significantly 
correlated with brain activation it is still likely that androgen levels play a role in the 
differences between the two groups. It was thought that there are already differences in 
brain function and structure in women with PCOS independent of current hormonal 
levels. Although no specific data exists to support this in human studies animal studies  
by Abbott et al.[281] reported that excessive androgen exposure prenatally may result 
in remarkable phenotypical similarities to women with PCOS, suggesting a foetal 
origin for this syndrome which may also have effects on organisation of the brain.  
These data clearly suggest that changes in white matter microstructure occur relatively 
early in our cohort of PCOS aged between 18 and 45 years of age and this was reflected 
by the decrease in axial diffusivity and an increase in tissue volume fraction in the 
anterior corpus callosum. Although no correlation was seen between cognitive function 
and white matter microstructure, risk factors such as insulin resistance and 
hyperandrogenaemia may play a role in these changes. This was an observational case 
control study and a therapeutic trial of intervention in the form of anti-androgenic 
therapy or insulin sensitising agents would help in assessing the role of these risk 
factors further.  
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CHAPTER 5 
Discussion 
Polycystic ovary syndrome (PCOS) was associated with both subtle decrements of 
cognitive function and alterations in microstructure of brain white matter. These 
differences were not attributable to BMI, which was closely matched between groups as 
was general intelligence. PCOS is one of the most common metabolic syndromes, 
affecting up to 10% of women of reproductive age [163]. Many body systems are 
affected in PCOS resulting in several health complications including menstrual 
dysfunction, infertility, hirsutism, acne, obesity, and metabolic syndrome. The public 
health importance of PCOS is amplified by the association with the risk of developing  
type 2 diabetes mellitus and possibly cardiovascular disease [127]. 
Traditional approaches to treatment of PCOS has focussed on the management of 
infertility and reducing cardiovascular risk. The results of my study suggest that the 
potential consequences of PCOS are wider, and the possibility that PCOS represents a 
midlife risk state for cognitive decline in old age should be explored. The case control 
design effectively isolated two features of PCOS – insulin resistance and 
hyperandrogenaemia – as possible causes of the alterations in white matter structure 
and cognition that were observed. Attention to these specific factors would help to 
define such a risk state and potential treatments more precisely. 
The current findings suggest a subtle but widespread erosion of cognitive performance. 
In an internet-based computerised study, Barnard et al hypothesised that women with 
PCOS would display enhanced cognitive performance on sexually dimorphic tasks 
[177]. However, no difference was found in performance of mental rotation or spatial 
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location tasks. Contrary to expectation, women with PCOS showed impaired 
performance on reaction time and word recognition tasks. Schattmann and Sherwin 
similarly found no differences on tests of mental rotation, spatial visualisation, or 
spatial perception in PCOS [208] . However, subjects with PCOS performed less well 
on tests of verbal fluency, verbal memory, manual dexterity, and visuospatial working 
memory. Previous studies have often been limited by poor case-control matching. For 
example, Barry et al found evidence of better visuospatial task performance in women 
with PCOS compared with subfertile controls, but this difference was no longer 
significant when age and BMI were controlled for in the analysis [271].  
In parallel with metabolic and cognitive differences, microstructural alterations in 
cerebral white matter were observed in the PCOS group. AD was reduced in a large 
portion of the white matter skeleton in PCOS and tissue volume fraction was increased 
in the anterior corpus callosum. Intriguingly, similar findings have been reported in 
studies on sexual dimorphism. For example, Kumar et al [279] found widespread 
reductions of axial and RD values in the male brain. The corpus callosum is generally 
larger in males. Further, a study with myelin-water fraction imaging has illustrated 
increased myelin density in males in the rostral body and posterior midbody of the 
corpus callosum [280], possibly concordant with our findings of increased f in the 
anterior part of the corpus callosum even though these studies address structural 
characteristics that are not necessarily closely correlated. One interpretation of the 
findings in the present study, therefore, is that an influence of androgens on brain 
structure produces alterations in PCOS that parallel the characteristics of the male 
brain. 
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The finding of a positive association between androgens and AD within the PCOS 
group was a surprise, given evidence that white matter AD is reduced in PCOS. 
Hyperandrogenemia and insulin resistance in the PCOS group were associated with 
increasing AD, despite a mean reduction in the PCOS group as a whole. The likely 
explanation was a reversal of the normal relationship between microstructure and 
metabolic status in patients with PCOS, reflected in a significant group by insulin AUC 
interaction. These findings raise the possibility that the brain responds differently to the 
effect of androgens in PCOS.  
A more recent study by Soleman et al.[179] on the effects of PCOS on cognition sought 
to explore working memory before and after anti androgenic treatment using functional 
MRI.  Women with PCOS differed in brain activation in the inferior and superior 
parietal lobe and in the superior temporal lobe than control women but not in 
performance (number of errors and reaction time) during a working memory task. 
Similar significant differences in biochemical parameters (testosterone/ free androgen 
index and androstenedione) were noted in the PCOS group although this did not 
correlate with brain activity in the regions of interest. Following anti-androgenic 
treatment, the between-group differences in brain activation were no longer apparent. 
Although this study did not look at indices of insulin resistance, it was considered likely 
that the differences between the two groups were possibly related to the level of 
androgens. It may be possible that there are already differences in brain functions and 
structure in women with PCOS independent of current hormonal levels [281]. 
Alternatively, there may be significant heterogeneity among individuals that is 
currently not captured by the coarse diagnostic categories in current use. For example, 
there may be distinct subtypes of PCOS with and without insulin resistance that differ 
in a variety of ways that are not yet fully understood; similarly, the presence of 
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increased insulin resistance in some BMI-matched controls suggests heterogeneity in 
the healthy population. 
Previous studies have reported differences in diffusion metrics in both type 2 diabetes 
[202] and obesity. Type 2 diabetes is associated with increases in AD in a number of 
specific tracts. Studies in obesity are less consistent, with at least 1 study reporting 
effects that vary by anatomical location in the brain and include both increases and 
decreases of AD in different regions [203, 282, 283]. These reports illustrate that there 
is no simple relationship between diffusion measures and better or worse white matter 
“integrity”[284]. The histological basis of alterations in disease states remains unclear 
and further work is required to aid the interpretation of direction as well as the 
magnitude of effects.  
Previous epidemiological studies suggest a complex relationship between BMI and 
dementia risk. Both high and low body mass states have been associated with future 
dementia risk, with evidence that the relationship might differ in mid and later life 
[285]. One recent report highlighted this complexity by showing a relationship between 
low body weight in midlife and dementia [286], contradicting previously held views 
about midlife obesity [285, 287] . The average age of individuals at entry to this recent 
retrospective study was 55; even less is known about the risk implications of BMI in 
the twenties and thirties, the age range relevant to the current study. 
 
Study Limitations 
There were some limitations to the experimental approach. Firstly, PCOS subjects were 
selected by the Rotterdam criteria, which embrace a less severe metabolic phenotype 
than other definitions of the syndrome. However, if anything this might be expected to 
underestimate the extent of white matter alteration in PCOS subjects with more severe 
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hyperandrogenism and insulin resistance. The Rotterdam criteria also encompass a 
heterogeneous group, hence future studies should compare distinct PCOS phenotypes, 
including lean subjects alone, in order to establish whether cognitive function and white 
matter microstructure are altered in all PCOS patients or only in some. Secondly, I did 
not capture information on physical activity levels in my study; future studies should 
look to record this in view of the possible relationship between sedentary behaviour and 
cognitive decline. Thirdly although cognitive function tests showed subtle differences 
in cognitive function across different domains, no clear correlation was found between 
cognition and white matter structure of relevant regions or connections. This related 
partly to power. Another factor was the unexpected interaction between group and 
metabolic factors in their influence on white matter structure. The National Adult 
Reading test although used as a widely accepted research tool in the assessment of 
premorbid intelligence may not be an entirely reliable tool in a cohort of patients not 
known to show any evidence of cognitive impairment as seen in this study.  
White matter tractography has several limitations. Although it is the only means of non 
invasive imaging of white matter tracts the issues identified relate to accurate 
identification of anatomical landmarks which can vary between different operators 
although customised tract based algorithms using region of interest approaches have 
been published [201, 288] which has helped to make this a reliable and reproducible 
imaging technique. The limitations of the diffusion tensor in areas of complex white 
matter architecture, where fibre tracts intersect, branch, or are otherwise partial volume 
averaged within a voxel, affect the ability of DTI fibre tractography to fully delineate 
an axonal pathway and may also lead to the generation of spurious tracks. 
Functional MRI is an emerging and useful tool in addition to diffusion tensor imaging 
to investigate and explore areas of activation and whether the differences in cognitive 
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function are significant. It would be interesting to see the effects of hormonal 
manipulation in the form of anti-androgen therapy and insulin sensitising agents on 
measures of diffusion and on functional MRI.    
 
Conclusion 
A key question that follows from these observations is whether alterations in brain 
structure and function can be reversed, reducing the risk of future cognitive decline. 
Interestingly, one study in PCOS suggested improvement in a single cognitive measure 
(verbal fluency), after combined treatment with an antiandrogen plus oestrogen [178]. 
Based on the current results, both insulin resistance and hyperandrogenism are potential 
targets, and advanced MRI has a potential role as a biomarker of treatment effect. 
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APPENDIX 1 
Total Variance Explained 
Component 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 4.978 35.555 35.555 4.978 35.555 35.555 
2 1.740 12.429 47.984 1.740 12.429 47.984 
3 1.526 10.899 58.883 1.526 10.899 58.883 
4 1.299 9.277 68.160 1.299 9.277 68.160 
5 .959 6.852 75.012    
6 .803 5.736 80.749    
7 .637 4.550 85.298    
8 .605 4.321 89.619    
9 .463 3.309 92.929    
10 .408 2.911 95.840    
11 .257 1.835 97.675    
12 .164 1.169 98.844    
13 .128 .912 99.756    
14 .034 .244 100.000    
Extraction Method (SPSS): Principal Component Analysis (PCA). First Principal Component accounts for 
35% of the variance across all cognitive test scores and was used as the summary score (General Cognition 
score) 
 
General Cognition Score (First Principal Component) was based on all of the cognitive 
tests that are appropriate (excluding tests of premorbid IQ, IQ (WASI) and Stroop  
which is known to be tricky in terms of covariance and PCA. The tests included in  
Principal component Analysis was derived from a combination of the following tests:  
Digit Span, Free and Cued Selective Reminding Test, Roy Osterrieth Complex Figure  
Test, Verbal Trails, Digit Symbol Substitution and the letter and semantic fluency test. 
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APPENDIX 2 
Group difference between PCOS and control in terms of summary score obtained  
through Principal Component analysis 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
                                                            Independent Samples Test 
 
 
REGR factor 
score 1 for 
analysis 
 F Sig (2-
tailed 
   t Mean Difference 
Equal variance 
assumed 
5.218 0.007    2.878 
 
0.8727 
Equal variances not 
assumed 
0.008    2.878 0.8727 
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